Perrigo (PRGO) 10-Q 12 May 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Apr. 03, 2021	May 07, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document period end date	Apr. 3, 2021
Document Transition Report	false
Entity File Number	001-36353
Entity registrant name	Perrigo Company plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	The Sharp Building,
Entity Address, Address Line Two	Hogan Place,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 TY74
Country Region	353
City Area Code	1
Local Phone Number	7094000
Title of 12(b) Security	Ordinary shares
Trading Symbol	PRGO
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity Shell Company	false
Entity common stock, shares outstanding		133,549,064
Entity central index key	0001585364
Current calendar year end date	--12-31
Document calendar year focus	2021
Document calendar period focus	Q1
Amendment flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands, shares in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Income Statement [Abstract]
Net sales	[1]	$ 1,010,000	$ 1,083,300
Cost of sales		641,600	689,600
Gross profit		368,400	393,700
Operating expenses
Distribution		21,600	20,200
Research and development		31,100	27,900
Selling		135,500	139,600
Administration		127,100	119,600
Restructuring		1,700	0
Total operating expenses		317,000	307,300
Operating income		51,400	86,400
Change in financial assets		0	(1,600)
Interest expense, net		32,000	28,900
Other (income) expense, net		2,400	1,700
Income from continuing operations before income taxes		17,000	57,400
Income tax expense (benefit)		14,200	(200)
Income from continuing operations		2,800	57,600
Income from discontinued operations, net of tax		35,300	48,800
Net income		$ 38,100	$ 106,400
Basic
Continuing operations (in dollars per share)		$ 0.02	$ 0.42
Discontinued operations (in dollars per share)		0.27	0.36
Basic earnings per share (in dollars per share)		0.29	0.78
Diluted
Continuing operations (in dollars per share)		0.02	0.42
Discontinued operations (in dollars per share)		0.26	0.35
Diluted earnings per share (in dollars per share)		$ 0.28	$ 0.77
Weighted-average shares outstanding
Basic (in shares)		133.2	136.2
Diluted (in shares)		134.6	137.3
[1]	Derived from the location of the entity that sells to a third party.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 38.1	$ 106.4
Other comprehensive income (loss):
Foreign currency translation adjustments	(111.6)	(92.2)
Change in fair value of derivative financial instruments, net of tax	(6)	(9.4)
Change in post-retirement and pension liability, net of tax	(0.7)	(1.9)
Other comprehensive income (loss), net of tax	(118.3)	(103.5)
Comprehensive income (loss)	$ (80.2)	$ 2.9

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands, shares in Millions	Apr. 03, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 470,900	$ 631,500
Accounts receivable, net of allowance for credit losses of $9.1 and $6.5, respectively	641,000	593,500
Inventories	1,136,100	1,059,400
Prepaid expenses and other current assets	251,500	182,200
Current assets held for sale	1,989,100	666,900
Total current assets	4,488,600	3,133,500
Property, plant and equipment, net	860,000	864,600
Operating lease assets	149,700	154,700
Goodwill and indefinite-lived intangible assets	3,059,300	3,102,700
Definite-lived intangible assets, net	2,366,300	2,481,500
Deferred income taxes	57,300	40,600
Non-current assets held for sale	0	1,364,000
Other non-current assets	343,600	346,800
Total non-current assets	6,836,200	8,354,900
Total assets	11,324,800	11,488,400
Liabilities and Shareholders’ Equity
Accounts payable	430,300	451,600
Payroll and related taxes	110,900	152,900
Accrued customer programs	134,500	128,500
Other accrued liabilities	267,900	183,100
Accrued income taxes	17,400	9,000
Current indebtedness	35,800	37,300
Current liabilities held for sale	450,000	419,600
Total current liabilities	1,446,800	1,382,000
Long-term debt, less current portion	3,525,300	3,527,600
Deferred income taxes	261,400	276,200
Non-current liabilities held for sale	0	108,300
Other non-current liabilities	533,300	539,200
Total non-current liabilities	4,320,000	4,451,300
Total liabilities	5,766,800	5,833,300
Commitments and contingencies - Refer to Note 15
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized	0	0
Ordinary shares, €0.001 par value per share, 10,000 shares authorized	7,101,300	7,118,200
Accumulated other comprehensive income	276,700	395,000
Retained earnings (accumulated deficit)	(1,820,000)	(1,858,100)
Total shareholders’ equity	5,558,000	5,655,100
Total liabilities and shareholders' equity	$ 11,324,800	$ 11,488,400
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding (in shares)	0	0
Ordinary shares, issued and outstanding (in shares)	133.5	133.1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Apr. 03, 2021USD ($)$ / sharesshares	Apr. 03, 2021€ / shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020€ / shares
Statement of Financial Position [Abstract]
Allowance for credit losses | $	$ 9.1		$ 6.5
Stockholders' Equity:
Preferred shares, par value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001
Preferred shares, authorized (shares)	10,000,000		10,000,000
Ordinary shares, par value (in EUR per share) | € / shares		€ 0.001		€ 0.001
Ordinary shares, authorized (shares)	10,000,000,000		10,000,000,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity Statement - USD ($) $ in Thousands, shares in Millions	Total	Ordinary Shares Issued	Accumulated Other Comprehensive Income	Retained Earnings (Accumulated Deficit)
Beginning balance (shares) at Dec. 31, 2019		136.1
Balance, beginning at Dec. 31, 2019	$ 5,803,800	$ 7,359,900	$ 139,400	$ (1,695,500)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	106,400			106,400
Other comprehensive loss	(103,500)		(103,500)
Restricted stock plan (shares)		0.3
Compensation for stock options	800	$ 800
Compensation for restricted stock	15,400	15,400
Cash dividends	(30,900)	$ (30,900)
Shares withheld for payment of employees' withholding tax liability (shares)		(0.1)
Shares withheld for payment of employees' withholding tax liability	(5,600)	$ (5,600)
Ending balance (shares) at Mar. 28, 2020		136.3
Balance, ending at Mar. 28, 2020	5,786,400	$ 7,339,600	35,900	(1,589,100)
Beginning balance (shares) at Dec. 31, 2020		133.1
Balance, beginning at Dec. 31, 2020	5,655,100	$ 7,118,200	395,000	(1,858,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	38,100			38,100
Other comprehensive loss	(118,300)		(118,300)
Restricted stock plan (shares)		0.6
Compensation for stock options	400	$ 400
Compensation for restricted stock	24,600	24,600
Cash dividends	(32,600)	$ (32,600)
Shares withheld for payment of employees' withholding tax liability (shares)		(0.2)
Shares withheld for payment of employees' withholding tax liability	(9,300)	$ (9,300)
Ending balance (shares) at Apr. 03, 2021		133.5
Balance, ending at Apr. 03, 2021	$ 5,558,000	$ 7,101,300	$ 276,700	$ (1,820,000)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2020	Sep. 28, 2019
Statement of Stockholders' Equity [Abstract]
Dividends paid (in dollars per share)	$ 0.24	$ 0.23

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Cash Flows From (For) Operating Activities
Net income	$ 38,100	$ 106,400
Adjustments to derive cash flows:
Depreciation and amortization	90,400	93,100
Share-based compensation	25,000	16,200
Change in financial assets	0	(1,600)
Restructuring charges	1,700	0
Deferred income taxes	(21,900)	6,700
Amortization of debt premium	(700)	(700)
Other non-cash adjustments, net	7,900	(14,000)
Subtotal	140,500	206,100
Increase (decrease) in cash due to:
Accounts receivable	(30,300)	(67,600)
Inventories	(83,200)	36,500
Prepaid expenses	(14,700)	(33,400)
Accounts payable	18,500	53,800
Payroll and related taxes	(45,900)	(18,400)
Accrued customer programs	(42,700)	(13,600)
Accrued liabilities	8,500	11,100
Accrued income taxes	27,000	3,800
Other, net	22,500	(6,500)
Subtotal	(140,300)	(34,300)
Net cash from (for) operating activities	200	171,800
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	1,400	1,800
Acquisitions of businesses, net of cash acquired	0	(11,300)
Asset acquisitions	(70,300)	(32,700)
Additions to property, plant and equipment	(45,400)	(33,800)
Other investing, net	300	1,200
Net cash from (for) investing activities	(114,000)	(74,800)
Cash Flows From (For) Financing Activities
Borrowings (repayments) of revolving credit agreements and other financing, net	0	102,000
Cash dividends	(32,600)	(30,900)
Other financing, net	(10,700)	(6,400)
Net cash from (for) financing activities	(43,300)	64,700
Effect of exchange rate changes on cash and cash equivalents	(3,900)	(5,600)
Net increase (decrease) in cash and cash equivalents	(161,000)	156,100
Cash and cash equivalents of continuing operations, beginning of period	631,500	344,500
Cash and cash equivalents discontinued operations, beginning of period	10,000	9,800
Less cash and cash equivalents discontinued operations, end of period	9,600	18,700
Cash and cash equivalents of continuing operations, end of period	$ 470,900	$ 491,700

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Apr. 03, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES General Information The Company Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries. Our vision is to make lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold . We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business ("RX business") to Altaris Capital Partners, LLC ("Altaris"). The financial results of our RX business, which were previously reported in our Prescription Pharmaceuticals ("RX") segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of our RX business are reflected as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets for all periods presented. Refer to Note 8 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Condensed Consolidated Financial Statements relate to our continuing operations. Segment Reporting Our reporting and operating segments are as follows: • Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada. • Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020. Allowance for Credit Losses Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and for reasonable and supportable forecasts. Historical credit loss experience provides the primary basis for estimation of expected credit losses. Adjustments to historical loss information may be made for significant changes in a geographic location’s economic conditions. Receivables that do not share risk characteristics are evaluated on an individual basis. These receivables are not included in the collective evaluation. The allowance for credit losses is a valuation account that is deducted from the instruments’ cost basis to present the net amount expected to be collected. Trade receivables and contract assets are charged off against the allowance when the balance is no longer deemed collectible. The following table presents the allowance for credit losses activity (in millions): Three Months Ended April 3, March 28, Beginning balance $ 6.5 $ 6.0 Provision for credit losses, net 2.9 0.4 Receivables written-off — — Recoveries collected (0.2) — Currency translation adjustment (0.1) (0.2) Ending balance $ 9.1 $ 6.2

Revenue Recognition

Revenue Recognition	3 Months Ended
	Apr. 03, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	REVENUE RECOGNITION Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products. Disaggregation of Revenue We generated net sales in the following geographic locations (1) (in millions): Three Months Ended April 3, March 28, U.S. $ 611.3 $ 670.7 Europe (2) 355.3 372.6 All other countries (3) 43.4 40.0 Total net sales $ 1,010.0 $ 1,083.3 (1) Derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $4.5 million and $3.8 million for the three months ended April 3, 2021, and March 28, 2020, respectively. (3) Includes net sales generated primarily in Mexico, Australia and Canada. Product Category The following is a summary of our net sales by category (in millions): Three Months Ended April 3, March 28, CSCA (1) Upper respiratory $ 114.0 $ 154.6 Digestive health 113.5 106.9 Pain and sleep-aids 92.4 120.4 Nutrition 92.0 102.2 Healthy lifestyle 75.5 85.8 Oral self-care 73.7 55.3 Skincare and personal hygiene 53.3 46.7 Vitamins, minerals, and supplements 7.8 6.4 Other CSCA (2) 18.3 22.3 Total CSCA 640.5 700.6 CSCI Skincare and personal hygiene 107.0 94.7 Vitamins, minerals, and supplements 59.0 48.5 Healthy lifestyle 50.3 43.6 Pain and sleep-aids 49.0 46.8 Upper respiratory 42.9 84.1 Oral self-care 25.5 23.2 Digestive health 8.5 6.0 Other CSCI (3) 27.3 35.8 Total CSCI 369.5 382.7 Total net sales $ 1,010.0 $ 1,083.3 (1) Includes net sales from our OTC contract manufacturing business. (2) Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. (3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $63.1 million and $49.2 million for the three months ended April 3, 2021, and March 28, 2020, respectively. We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery. Contract Balances The following table provides information about contract assets from contracts with customers (in millions): Balance Sheet Location April 3, December 31, Short-term contract assets Prepaid expenses and other current assets $ 18.4 $ 19.7

Acquisitions

Acquisitions	3 Months Ended
	Apr. 03, 2021
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS Acquisitions Accounted for as a Business Combination During the Year Ended December 31, 2020 Eastern European OTC Dermatological Brands Acquisition On October 30, 2020, we acquired three Eastern European OTC dermatological brands ("Eastern European Brands"), skincare brands Emolium ® and Iwostin ® and hair loss treatment brand Loxon ® , from Sanofi. The transaction closed for €53.3 million ($62.3 million). We capitalized $52.5 million as brand-named intangible assets and allocated the remainder of the purchase price to goodwill, inventory, customer relationships and deferred tax assets. The addition of these market-leading OTC brands complements our already robust skincare portfolio and adds scale to our Eastern European business. The acquisition also serves as another step for Perrigo’s CSCI growth plans and provides new opportunities for self-care revenue synergy in the European markets. The operating results of the brands will be reported within our CSCI segment. The acquisition of the Eastern European Brands was accounted for as a business combination and has been reported in our Consolidated Statements of Operations as of the acquisition date. We are in the process of gathering significant relevant information needed to complete the valuation for the assets acquired and liabilities assumed. As a result, the initial accounting for the acquisition is incomplete. The provisional acquisition amounts recognized for assets acquired and liabilities assumed will be finalized as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized. The goodwill arising from the acquisition consists largely of the assembled workforce, and the cost and revenue synergies expected from integrating the business into the CSCI segment. The goodwill was allocated to our CSCI segment, none of which is deductible for income tax purposes. The definite-lived intangible assets acquired consisted of brands and customer relationships which are being amortized over a weighted average useful life of approximately 18.8 years. Both the brands and customer relationships were valued using the multi-period excess earnings method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. Oral Care Assets of High Ridge Brands On April 1, 2020, we acquired the oral care assets of High Ridge Brands ("Dr. Fresh") for total purchase consideration of $113.0 million, subject to customary adjustments, including a working capital settlement. After such adjustments as of December 31, 2020, total cash consideration paid was $106.2 million net of $2.0 million that we allocated as prepayment of contract consideration for transitional services to be received related to the transaction. This acquisition includes the children’s oral care value brand, Firefly ® , in addition to the REACH ® and Dr. Fresh ® brands, and a licensing portfolio. The U.S. operations, which represent a significant portion of the business, are reported in our CSCA segment and the non-U.S. operations are reported in our CSCI segment. The following table summarizes the consideration paid for Dr. Fresh and the amounts of the assets acquired and liabilities assumed (in millions): Oral Care Assets of High Ridge Brands (Dr. Fresh) Purchase price paid $ 106.2 Assets acquired: Accounts receivable 13.1 Inventories 22.2 Prepaid expenses and other current assets 0.4 Property, plant and equipment, net 0.7 Operating lease assets 2.6 Goodwill 17.2 Distribution and license agreements and supply agreements $ 2.2 Developed product technology, formulations, and product rights 0.1 Customer relationships and distribution networks 20.6 Trademarks, trade names, and brands 43.2 Total intangible assets $ 66.1 Total assets $ 122.3 Liabilities assumed: Accounts payable $ 6.1 Other accrued liabilities 3.8 Payroll and related taxes 0.7 Accrued customer programs 3.0 Other non-current liabilities 2.5 Total liabilities $ 16.1 Net assets acquired $ 106.2 The goodwill of $17.2 million arising from the acquisition consists largely of the anticipated growth from new product sales, sales to new customers, the assembled workforce, and the synergies expected from combining the operations of Dr. Fresh into Perrigo. The goodwill is attributable to our CSCA segment and is tax deductible for income tax purposes. The definite-lived intangible assets acquired consisted of trademarks and trade names, license agreements, and customer relationships, which are being amortized over a weighted average useful life of approximately 17.8 years . Customer relationships were valued using the multi-period excess earnings method. Trademarks and trade names and developed technology were valued using the relief from royalty method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. The opening balance sheet is final. Pro Forma Impact of Business Combinations The following table presents unaudited pro forma information as if the acquisitions of Dr. Fresh and the Eastern European Brands occurred on January 1, 2019, and had been combined with the results reported in our Condensed Consolidated Statements of Operations for all periods presented (in millions): Three Months Ended (Unaudited) March 28, Net sales $ 1,119.1 Income from continuing operations $ 62.6 The unaudited pro forma information is presented for information purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. The unaudited pro forma information presented above includes adjustments primarily for amortization charges for acquired intangible assets, depreciation of property, plant and equipment that have been revalued, certain acquisition-related charges, and related tax effects. Acquisitions During the Three Months Ended March 28, 2020 Dexsil ® On February 13, 2020, we acquired Dexsil ® , a silicon supplement brand, from RXW Group Nv, for total cash consideration paid of approximately $8.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized the consideration paid as a brand-named intangible asset. We began amortizing the brand intangible over a 25-year useful life. Operating results attributable to the product are included within our CSCI segment. Steripod ® On January 3, 2020, we acquired Steripod ® , a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. Total consideration paid was $26.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized $25.1 million as a brand-named intangible asset. The remainder of the purchase price was allocated to working capital. We began amortizing the brand intangible asset over a 25-year useful life. Operating results attributable to Steripod ®

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Apr. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): December 31, Purchase accounting adjustments Currency translation adjustments April 3, CSCA $ 1,905.0 $ 2.4 $ (1.9) $ 1,905.5 CSCI (1) 1,190.7 (2.4) (41.5) 1,146.8 Total goodwill $ 3,095.7 $ — $ (43.4) $ 3,052.3 (1) We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and April 3, 2021. Intangible Assets Intangible assets and related accumulated amortization consisted of the following (in millions): April 3, 2021 December 31, 2020 Gross Accumulated Gross Accumulated Indefinite-lived intangibles: Trademarks, trade names, and brands $ 4.3 $ — $ 4.3 $ — In-process research and development 2.7 — 2.7 — Total indefinite-lived intangibles $ 7.0 $ — $ 7.0 $ — Definite-lived intangibles: Distribution and license agreements and supply agreements $ 73.2 $ 55.1 $ 74.8 $ 55.4 Developed product technology, formulations, and product rights 301.8 180.5 303.3 177.3 Customer relationships and distribution networks 1,873.9 830.9 1,920.5 823.7 Trademarks, trade names, and brands 1,534.4 350.5 1,581.5 342.2 Non-compete agreements 2.4 2.4 2.9 2.9 Total definite-lived intangibles $ 3,785.7 $ 1,419.4 $ 3,883.0 $ 1,401.5 Total intangible assets $ 3,792.7 $ 1,419.4 $ 3,890.0 $ 1,401.5

Inventories

Inventories	3 Months Ended
	Apr. 03, 2021
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Major components of inventory were as follows (in millions): April 3, December 31, Finished goods $ 648.2 $ 574.1 Work in process 234.7 220.4 Raw materials 253.2 264.9 Total inventories $ 1,136.1 $ 1,059.4

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions): April 3, 2021 December 31, 2020 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Measured at fair value on a recurring basis: Assets: Investment securities $ 2.9 $ — $ — $ 2.5 $ — $ — Foreign currency forward contracts — 7.2 — — 9.8 — Cross-currency swap — 5.7 — — 6.3 — Total assets $ 2.9 $ 12.9 $ — $ 2.5 $ 16.1 $ — Liabilities: Foreign currency forward contracts $ — $ 6.5 $ — $ — $ 7.9 $ — Total liabilities $ — $ 6.5 $ — $ — $ 7.9 $ — There were no transfers within Level 3 fair value measurements during the three months ended April 3, 2021 or the year ended December 31, 2020. Royalty Pharma Contingent Milestone Receipts During the year ended December 31, 2020, Royalty Pharma payments from Biogen for Tysabri ® sales, as defined in the agreement between the parties, did not exceed the 2020 global net sales threshold. Therefore, we were not entitled to receive the remaining contingent milestone payment. As of December 31, 2020, there were no contingent milestone payments outstanding. The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions): Three Months Ended March 28, Beginning balance $ 95.3 Change in fair value 1.6 Ending balance $ 96.9 We valued our contingent milestone payment from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri ® that are received by Royalty Pharma until the contingent milestones are resolved. As of March 28, 2020, volatility and the estimated fair value of the milestones had a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. Rate of return and the estimated fair value of the milestones had an inverse relationship, such that a lower rate of return correlates with a higher estimated fair value of the contingent milestone payments. We assessed volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return: Three Months Ended March 28, Volatility 35.0 % Rate of return 7.29 % During the three months ended March 28, 2020, the fair value of the Royalty Pharma contingent milestone payment related to 2020 increased by $1.6 million to $96.9 million, driven by higher volatility, higher projected global net sales of Tysabri ® compared to the estimates in the prior period, and the estimated probability of achieving the earn-out. As of December 31, 2020, there were no contingent milestone payments outstanding and, accordingly, no asset recorded in the Condensed Consolidated Balance Sheet. Non-recurring Fair Value Measurements The non-recurring fair values represent only those assets whose carrying values were adjusted to fair value during the reporting period. Fixed Rate Long-term Debt Our fixed rate long-term debt consisted of the following (in millions): April 3, December 31, Level 1 Level 2 Level 1 Level 2 Public Bonds Carrying Value (excluding discount) $ 2,760.0 $ — $ 2,760.0 $ — Fair value $ 2,863.7 $ — $ 3,031.1 $ — Private placement note Carrying value (excluding premium) $ — $ 158.8 $ — $ 164.9 Fair value $ — $ 176.6 $ — $ 177.5 The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.

Investments

Investments	3 Months Ended
	Apr. 03, 2021
Investments [Abstract]
Investments	INVESTMENTS The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions): Measurement Category Balance Sheet Location April 3, December 31, Fair value method Prepaid expenses and other current assets $ 2.9 $ 2.5 Fair value method (1) Other non-current assets $ 1.5 $ 1.9 Equity method Other non-current assets $ 69.1 $ 69.8 (1) Measured at fair value using the Net Asset Value practical expedient. The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions): Three Months Ended Measurement Category Income Statement Location April 3, March 28, Fair value method Other (income) expense, net $ — $ 2.9 Equity method Other (income) expense, net $ 0.7 $ (0.7)

Discontinued Operations

Discontinued Operations	3 Months Ended
	Apr. 03, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations Our discontinued operations primarily consist of our RX segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “RX business”). On March 1, 2021, we announced a definitive agreement to sell our RX business to Altaris for total consideration of $1.55 billion, including $1.5 billion in cash and the assumption of more than $50.0 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners. On March 8, 2021, we purchased an Abbreviated New Drug Application ("ANDA") for a generic topical lotion for $53.3 million, which was the largest contingent purchase obligation to be assumed by Altaris and increased the cash consideration we will receive upon completion of the sale of the RX business to $1.55 billion. The transaction is subject to antitrust and other customary closing conditions and is expected to close in the third quarter of 2021. As of March 1, 2021, we determined that the RX business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results have been reflected in our consolidated financial statements as a discontinued operation and its assets and liabilities have been classified as held for sale. We ceased recording depreciation and amortization on the RX business assets from March 1, 2021. We have not allocated any general corporate overhead to the discontinued operation. Under the terms of the agreement, we will provide transition services for up to 24 months after the close of the transaction and also enter into a reciprocal supply agreement pursuant to which Perrigo will supply certain products to the RX business and the RX business will supply certain products to Perrigo. Under the agreed form, the supply agreements will have a term of four years, extendable up to seven years by the party who is the purchaser of the products under such agreement. We will also extend distribution rights to the RX business for certain OTC products owned and manufactured by Perrigo that may be fulfilled through pharmacy channels, in return for a share of the net profits. The agreement provides that Perrigo will retain certain pre-closing liabilities arising out of antitrust (refer to Note 15 - Contingencies under the header "Price-Fixing Lawsuits") and opioid matters and the Company’s Albuterol recall, subject to, in each case, the buyer's obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on the buyer's obligation of $50.0 million. Income from discontinued operations, net of tax was as follows (in millions): Three Months Ended April 3, March 28, Net sales $ 200.1 $ 257.7 Cost of sales 138.3 165.8 Gross profit 61.8 91.9 Operating expenses Distribution 3.3 4.0 Research and development 13.4 13.6 Selling 7.4 7.3 Administration 18.2 6.5 Other operating expense (income) (0.9) 1.1 Total operating expenses 41.4 32.5 Operating income $ 20.4 $ 59.4 Interest expense, net 0.6 1.4 Other (income) expense, net (1.5) 0.7 Income before income taxes 21.3 57.3 Income tax expense (benefit) (14.0) 8.5 Income from discontinued operations, net of tax $ 35.3 $ 48.8 During the three months ended April 3, 2021, we incurred $9.3 million of separation costs related to the sale of the RX business, which are recorded in administration expenses. Select cash flow information related to discontinued operations was as follows (in millions): Three Months Ended April 3, March 28, Cash flows from discontinued operations operating activities: Depreciation and amortization $ 15.3 $ 24.0 Cash flows from discontinued operations investing activities: Asset acquisitions $ (69.7) $ (0.1) Additions to property, plant and equipment $ (3.2) $ (2.9) Asset acquisitions related to discontinued operations consisted of two ANDAs purchased under a contractual arrangement entered into on May 15, 2015 with a third party that specializes in research and development and obtaining approval for various drug candidates to develop specific products. On December 31, 2020, we purchased an ANDA for a generic topical gel for $16.4 million, which was subsequently paid during the three months ended April 3, 2021 and on March 8, 2021, we purchased an ANDA for a generic topical lotion for $53.3 million. The generic topical lotion acquisition is being assumed by Altaris in connection with the sale of the RX business. The assets and liabilities classified as held for sale were as follows (in millions): April 3, December 31, Cash and cash equivalents $ 9.6 $ 10.0 Accounts receivable, net of allowance for credit losses of $1.1 and $1.1, respectively 419.9 460.7 Inventories 136.8 140.8 Prepaid expenses and other current assets 29.7 55.4 Current assets held for sale* 666.9 Property, plant and equipment, net 126.4 131.4 Operating lease assets 29.6 31.3 Goodwill and indefinite-lived intangible assets 678.7 681.2 Definite-lived intangible assets, net 533.0 492.8 Deferred income taxes 3.0 3.6 Other non-current assets 22.4 23.7 Non-current assets held for sale* 1,364.0 Total assets held for sale $ 1,989.1 $ 2,030.9 Accounts payable $ 101.1 $ 92.2 Payroll and related taxes 16.7 22.3 Accrued customer programs 185.9 237.4 Other accrued liabilities 47.4 67.2 Current indebtedness 0.5 0.5 Current liabilities held for sale* 419.6 Long-term debt, less current portion 0.6 0.7 Deferred income taxes 2.9 3.1 Other non-current liabilities 94.9 104.5 Non-current liabilities held for sale* 108.3 Total liabilities held for sale $ 450.0 $ 527.9 *As of April 3, 2021, the non-current assets and liabilities of the RX business have been reclassified to current assets and liabilities held for sale, respectively, due to the expected completion of the sale of the business in the third quarter of 2021, as discussed above.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	3 Months Ended
	Apr. 03, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Cross Currency Swaps On August 15, 2019, we entered into a cross-currency swap designated as a net investment hedge to hedge the EUR currency exposure of our net investment in European operations. This agreement is a contract to exchange floating-rate Euro payments for floating-rate U.S. dollar payments through August 15, 2022. The payments are based on a notional basis of €450.0 million ($498.0 million) and settle quarterly. Interest Rate Swaps There were no active designated or non-designated interest rate swaps as of April 3, 2021 or December 31, 2020. Foreign Currency Forwards Foreign currency forward contracts were as follows (in millions): Notional Amount April 3, December 31, European Euro (EUR) $ 270.7 $ 312.6 Israeli Shekel (ILS) 74.1 94.4 United States Dollar (USD) 63.4 101.5 Chinese Yuan (CNY) 50.4 49.1 British Pound (GBP) 44.8 92.3 Danish Krone (DKK) 44.0 65.2 Swedish Krona (SEK) 30.1 41.2 Canadian Dollar (CAD) 27.8 36.8 Polish Zloty (PLZ) 18.3 21.8 Mexican Peso (MPX) 14.8 15.6 Norwegian Krone (NOK) 9.7 7.8 Australian Dollar (AUD) 9.1 11.3 Romanian New Leu (RON) 4.8 3.6 Switzerland Franc (CHF) 4.6 8.2 Turkish Lira (TRY) 3.7 4.0 Other 2.4 2.3 Total $ 672.7 $ 867.7 The maximum term of our forward currency exchange contracts is 60 months. Effects of Derivatives on the Financial Statements The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects. The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions): Asset Derivatives Fair Value Balance Sheet Location April 3, December 31, Designated derivatives: Foreign currency forward contracts Prepaid expenses and other current assets $ 5.6 $ 5.0 Foreign currency forward contracts Other non-current assets 0.4 0.5 Cross-currency swap Other non-current assets 5.7 6.3 Total designated derivatives $ 11.7 $ 11.8 Non-designated derivatives: Foreign currency forward contracts Prepaid expenses and other current assets $ 1.2 $ 4.3 Liability Derivatives Fair Value Balance Sheet Location April 3, December 31, Designated derivatives: Foreign currency forward contracts Other accrued liabilities $ 3.6 $ 5.5 Non-designated derivatives: Foreign currency forward contracts Other accrued liabilities $ 2.9 $ 2.4 The following tables summarize the effect of derivative instruments designated as hedging instruments in Accumulated Other Comprehensive Income ("AOCI") (in millions): Three Months Ended April 3, 2021 Instrument Amount of Gain/(Loss) Recorded in OCI (1) Classification of Gain/(Loss) Reclassified from AOCI into Earnings Amount of Gain/(Loss) Reclassified from AOCI into Earnings Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing Cash flow hedges: Interest rate swap agreements $ — Interest expense, net $ (0.5) Interest expense, net $ — Foreign currency forward contracts 1.7 Net sales (0.9) Net sales — Cost of sales (1.4) Cost of sales 0.1 Other (income) expense, net (0.1) $ 1.7 $ (2.8) $ — Net investment hedges: Cross-currency swap $ (0.5) Interest expense, net $ 1.0 (1) Net loss of $13.4 million is expected to be reclassified out of AOCI into earnings during the next 12 months. Three Months Ended March 28, 2020 Instrument Amount of Gain/(Loss) Recorded in OCI Classification of Gain/(Loss) Reclassified from AOCI into Earnings Amount of Gain/(Loss) Reclassified from AOCI into Earnings Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing Cash flow hedges: Interest rate swap agreements $ — Interest expense, net $ (0.5) Interest expense, net $ — Foreign currency forward contracts 9.3 Net sales (0.4) Net sales — Cost of sales (1.0) Cost of sales 0.4 $ 9.3 $ (1.9) $ 0.4 Net investment hedges: Cross-currency swap $ (15.0) Interest expense, net $ 2.8 The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions): Three Months Ended Non-Designated Derivatives Income Statement April 3, March 28, Foreign currency forward contracts Other (income) expense, net $ (4.8) $ 6.2 Interest expense, net 1.2 0.9 $ (3.6) $ 7.1 The classification and amount of gain/(loss) recognized in earnings on fair value and hedging relationships were as follows (in millions): Three Months Ended April 3, 2021 Net Sales Cost of Sales Interest Expense, net Other (Income) Expense, net Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded $ 1,010.0 $ 641.6 $ 32.0 $ 2.4 The effects of cash flow hedging: Gain (loss) on cash flow hedging relationships Foreign currency forward contracts Amount of gain or (loss) reclassified from AOCI into earnings $ (0.9) $ (1.4) $ — $ — Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach $ — $ 0.1 $ — $ (0.1) Interest rate swap agreements Amount of gain or (loss) reclassified from AOCI into earnings $ — $ — $ (0.5) $ — Three Months Ended March 28, 2020 Net Sales Cost of Sales Interest Expense, net Other (Income) Expense, net Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded $ 1,083.3 $ 689.6 $ 28.9 $ 1.7 The effects of cash flow hedging: Gain (loss) on cash flow hedging relationships Foreign currency forward contracts Amount of gain or (loss) reclassified from AOCI into earnings $ (0.4) $ (1.0) $ — $ — Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach $ — $ 0.4 $ — $ — Interest rate swap agreements Amount of gain or (loss) reclassified from AOCI into earnings $ — $ — $ (0.5) $ —

Leases

Leases	3 Months Ended
	Apr. 03, 2021
Leases [Abstract]
Leases	LEASES The balance sheet locations of our lease assets and liabilities were as follows (in millions): Assets Balance Sheet Location April 3, December 31, Operating Operating lease assets $ 149.7 $ 154.7 Finance Other non-current assets 32.2 29.8 Total $ 181.9 $ 184.5 Liabilities Balance Sheet Location April 3, December 31, Current Operating Other accrued liabilities $ 27.1 $ 28.3 Finance Current indebtedness 5.2 6.7 Non-Current Operating Other non-current liabilities 128.2 132.5 Finance Long-term debt, less current portion 24.3 20.2 Total $ 184.8 $ 187.7 The below table shows our lease assets and liabilities by reporting segment (in millions): Assets Liabilities Operating Financing Operating Financing April 3, December 31, April 3, December 31, April 3, December 31, April 3, December 31, CSCA $ 74.2 $ 75.9 $ 16.3 $ 16.7 $ 73.9 $ 75.8 $ 16.7 $ 17.0 CSCI 32.9 34.4 8.7 5.9 33.7 35.2 5.5 2.5 Unallocated 42.6 44.4 7.2 7.2 47.7 49.8 7.3 7.4 Total $ 149.7 $ 154.7 $ 32.2 $ 29.8 $ 155.3 $ 160.8 $ 29.5 $ 26.9 Lease expense was as follows (in millions): Three Months Ended April 3, March 28, Operating leases (1) $ 9.8 $ 9.6 Finance leases Amortization $ 1.5 $ 1.0 Interest 0.2 0.2 Total finance leases $ 1.7 $ 1.2 (1) Includes short-term leases and variable lease costs, which are immaterial. The annual future maturities of our leases as of April 3, 2021 are as follows (in millions): Operating Leases Finance Leases Total 2021 $ 24.0 $ 4.5 $ 28.5 2022 26.2 5.5 31.7 2023 18.9 3.8 22.7 2024 15.9 2.3 18.2 2025 13.9 2.2 16.1 After 2025 80.5 15.8 96.3 Total lease payments 179.4 34.1 213.5 Less: Interest 24.1 4.6 28.7 Present value of lease liabilities $ 155.3 $ 29.5 $ 184.8 Our weighted average lease terms and discount rates are as follows: April 3, March 28, Weighted-average remaining lease term (in years) Operating leases 10.52 5.98 Finance leases 9.31 10.10 Weighted-average discount rate Operating leases 2.97 % 3.97 % Finance leases 2.76 % 3.42 % Our lease cash flow classifications are as follows (in millions): Three Months Ended April 3, March 28, Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 10.0 $ 8.9 Operating cash flows for finance leases $ 0.2 $ 0.2 Financing cash flows for finance leases $ 1.3 $ 0.9 Leased assets obtained in exchange for new finance lease liabilities $ 4.2 $ 1.5 Leased assets obtained in exchange for new operating lease liabilities $ 3.9 $ 4.9
Leases	LEASES The balance sheet locations of our lease assets and liabilities were as follows (in millions): Assets Balance Sheet Location April 3, December 31, Operating Operating lease assets $ 149.7 $ 154.7 Finance Other non-current assets 32.2 29.8 Total $ 181.9 $ 184.5 Liabilities Balance Sheet Location April 3, December 31, Current Operating Other accrued liabilities $ 27.1 $ 28.3 Finance Current indebtedness 5.2 6.7 Non-Current Operating Other non-current liabilities 128.2 132.5 Finance Long-term debt, less current portion 24.3 20.2 Total $ 184.8 $ 187.7 The below table shows our lease assets and liabilities by reporting segment (in millions): Assets Liabilities Operating Financing Operating Financing April 3, December 31, April 3, December 31, April 3, December 31, April 3, December 31, CSCA $ 74.2 $ 75.9 $ 16.3 $ 16.7 $ 73.9 $ 75.8 $ 16.7 $ 17.0 CSCI 32.9 34.4 8.7 5.9 33.7 35.2 5.5 2.5 Unallocated 42.6 44.4 7.2 7.2 47.7 49.8 7.3 7.4 Total $ 149.7 $ 154.7 $ 32.2 $ 29.8 $ 155.3 $ 160.8 $ 29.5 $ 26.9 Lease expense was as follows (in millions): Three Months Ended April 3, March 28, Operating leases (1) $ 9.8 $ 9.6 Finance leases Amortization $ 1.5 $ 1.0 Interest 0.2 0.2 Total finance leases $ 1.7 $ 1.2 (1) Includes short-term leases and variable lease costs, which are immaterial. The annual future maturities of our leases as of April 3, 2021 are as follows (in millions): Operating Leases Finance Leases Total 2021 $ 24.0 $ 4.5 $ 28.5 2022 26.2 5.5 31.7 2023 18.9 3.8 22.7 2024 15.9 2.3 18.2 2025 13.9 2.2 16.1 After 2025 80.5 15.8 96.3 Total lease payments 179.4 34.1 213.5 Less: Interest 24.1 4.6 28.7 Present value of lease liabilities $ 155.3 $ 29.5 $ 184.8 Our weighted average lease terms and discount rates are as follows: April 3, March 28, Weighted-average remaining lease term (in years) Operating leases 10.52 5.98 Finance leases 9.31 10.10 Weighted-average discount rate Operating leases 2.97 % 3.97 % Finance leases 2.76 % 3.42 % Our lease cash flow classifications are as follows (in millions): Three Months Ended April 3, March 28, Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 10.0 $ 8.9 Operating cash flows for finance leases $ 0.2 $ 0.2 Financing cash flows for finance leases $ 1.3 $ 0.9 Leased assets obtained in exchange for new finance lease liabilities $ 4.2 $ 1.5 Leased assets obtained in exchange for new operating lease liabilities $ 3.9 $ 4.9

Indebtedness

Indebtedness	3 Months Ended
	Apr. 03, 2021
Debt Disclosure [Abstract]
Indebtedness	INDEBTEDNESS Total borrowings outstanding are summarized as follows (in millions): April 3, December 31, Term loan 2019 Term loan due August 15, 2022 $ 600.0 $ 600.0 Notes and Bonds Coupon Due 5.105% July 28, 2023 (1) 158.8 164.9 4.000% November 15, 2023 215.6 215.6 3.900% December 15, 2024 700.0 700.0 4.375% March 15, 2026 700.0 700.0 3.150% June 15, 2030 750.0 750.0 5.300% November 15, 2043 90.5 90.5 4.900% December 15, 2044 303.9 303.9 Total notes and bonds 2,918.8 2,924.9 Other financing 60.1 57.4 Unamortized premium (discount), net (1.5) (0.3) Deferred financing fees (16.3) (17.1) Total borrowings outstanding 3,561.1 3,564.9 Current indebtedness (35.8) (37.3) Total long-term debt less current portion $ 3,525.3 $ 3,527.6 (1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate. We are in compliance with all covenants under our debt agreements as of April 3, 2021. Revolving Credit Agreements On March 8, 2018, we entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of April 3, 2021 or December 31, 2020. Other Financing We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no borrowings outstanding under the facilities as of April 3, 2021 or December 31, 2020. On June 17, 2020, we incurred debt of $34.3 million related to our equity method investment in Kazmira pursuant to two Promissory Notes, with $3.7 million, $5.8 million and $24.8 million to be settled in November 2020, May 2021 and November 2021, respectively. On December 8, 2020, we repaid the $3.7 million balance due on the November 2020 portion of the Promissory Notes. We have financing leases that are reported in the above table under "Other financing" (refer to Note 10 ).

Earnings Per Share and Sharehol

Earnings Per Share and Shareholders' Equity	3 Months Ended
	Apr. 03, 2021
Earnings Per Share [Abstract]
Earnings Per Share and Shareholders' Equity	EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY Earnings per Share A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): Three Months Ended April 3, March 28, Numerator: Income from continuing operations $ 2.8 $ 57.6 Income from discontinued operations, net of tax 35.3 48.8 Net income $ 38.1 $ 106.4 Denominator: Weighted average shares outstanding for basic EPS 133.2 136.2 Dilutive effect of share-based awards 1.4 1.1 Weighted average shares outstanding for diluted EPS 134.6 137.3 Anti-dilutive share-based awards excluded from computation of diluted EPS 1.8 1.7 Shareholders' Equity Share Repurchases

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Apr. 03, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Changes in our AOCI balances, net of tax were as follows (in millions): Fair Value of Derivative Financial Instruments, net of tax Foreign Currency Translation Adjustments Post-Retirement and Pension Liability Adjustments, net of tax Total AOCI Balance at December 31, 2020 $ (0.7) $ 407.3 $ (11.6) $ 395.0 OCI before reclassifications (8.8) (111.6) (0.7) (121.1) Amounts reclassified from AOCI 2.8 — — 2.8 Other comprehensive income (loss) $ (6.0) $ (111.6) $ (0.7) $ (118.3) Balance at April 3, 2021 $ (6.7) $ 295.7 $ (12.3) $ 276.7

Income Taxes

Income Taxes	3 Months Ended
	Apr. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The effective tax rates were as follows: Three Months Ended April 3, March 28, 84.0 % (0.4) % The effective tax rate for the three months ended April 3, 2021 increased compared to the prior period primarily due to the prior period tax benefits for reductions to the U.S. valuation allowance and the U.S. Coronavirus Aid, Relief and Economic Security ("CARES") Act, enacted in the first quarter of 2020, plus the current period net tax expense on intra-entity transfers of intellectual property. In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes." It removes certain exceptions to the general principles in ASC Topic 740 and improves consistent application of and simplifies GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. This guidance was effective for interim and annual reporting periods beginning after December 15, 2020. We adopted this guidance as of January 1, 2021, and the impact on our Consolidated Financial Statements was immaterial. Internal Revenue Service Audits of Perrigo Company, a U.S. Subsidiary Perrigo Company, our U.S. subsidiary ("Perrigo U.S."), is engaged in a series of tax disputes in the U.S. relating primarily to transfer pricing adjustments including income in connection with the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States, including the heartburn medication omeprazole. On August 27, 2014, we received a statutory notice of deficiency from the IRS relating to our fiscal tax years ended June 27, 2009, and June 26, 2010 (the “2009 tax year” and “2010 tax year”, respectively). On April 20, 2017, we received a second statutory notice of deficiency from the IRS for the fiscal tax years ended June 25, 2011 and June 30, 2012 (the “2011 tax year” and “2012 tax year”, respectively). Specifically, both statutory notices proposed adjustments related to the offshore reporting of profits on sales of omeprazole in the United States resulting from the assignment of an omeprazole distribution contract to an affiliate. In addition to the transfer pricing adjustments, which applied to all four tax years, the statutory notice of deficiency for the 2011 and 2012 tax years included adjustments for the capitalization and amortization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits related to ANDAs. We do not agree with the audit adjustments proposed by the IRS in either of the notices of deficiency. We paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and timely filed claims for refund on June 11, 2015 for the 2009 and 2010 tax years, and on June 7, 2017, for the 2011 and 2012 tax years. On August 15, 2017, following disallowance of such refund claims, we timely filed a complaint in the United States District Court for the Western District of Michigan seeking refunds of tax, interest, and penalties of $27.5 million for the 2009 tax year, $41.8 million for the 2010 tax year, $40.1 million for the 2011 tax year, and $24.7 million for the 2012 tax year, for a total of $134.1 million, plus statutory interest thereon from the dates of payment. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The previously scheduled trial date has been continued to May 25, 2021 for the refund case. The total amount of cumulative deferred charge that we are seeking to receive in this litigation is approximately $111.6 million, which reflects the impact of conceding that Perrigo U.S. should have received a 5.24% royalty on all omeprazole sales. That concession was previously paid and is the subject of the above refund claims. The issues outlined in the statutory notices of deficiency described above are continuing, and the IRS will likely carry forward the adjustments set forth therein as long as the drug is sold, in the case of the omeprazole issue, and for all post-2012 Paragraph IV filings that trigger patent infringement suits, in the case of the ANDA issue. On April 30, 2021, we filed a Notice of New Authority in our refund case in the Western District of Michigan alerting the court to a Tax Court decision in Mylan v. Comm'r that ruled in favor of the taxpayer on the identical ANDA issues we have before the court. On January 13, 2021, the IRS issued a 30-day letter with respect to its audit of our fiscal tax years ended June 29, 2013 (the "2013 tax year"), June 28, 2014 (the "2014 tax year"), and June 27, 2015 (the "2015 tax year" and together with the 2013 tax year and the 2014 tax year, the "2013-2015 tax years"). The IRS letter proposed, among other modifications, carryforwards of the transfer pricing adjustments regarding our profits from the distribution of omeprazole in the aggregate amount of $141.6 million and ANDA adjustments in the aggregate amount of $21.9 million. The 30-day letter also set forth adjustments described in the next two paragraphs. We timely filed a protest to the 30-day letter for those additional adjustments, but noting that due to the pending litigation described above, IRS Appeals will not consider the merits of the omeprazole or ANDA matters. We believe that we should prevail on the merits on both carryforward issues and have reserved for taxes and interest payable on the 5.24% deemed royalty on omeprazole through the tax year ended December 31, 2018. Beginning with the tax year ended December 31, 2019, we began reporting income commensurate with the 5.24% deemed royalty. We have not reserved for the ANDA-related issue described above. While we believe we should prevail on the merits of this case, the outcome remains uncertain. If our litigation position on the omeprazole issue is not sustained, the outcome for the 2009–2012 tax years could range from a reduction in the refund amount to denial of any refund. In addition, we expect that the outcome of the refund litigation could effectively bind future tax years. In that event, an adverse ruling on the omeprazole issue could have a material impact on subsequent periods, with additional tax liability in the range of $24.0 million to $112.0 million, not including interest and any applicable penalties. The 30-day letter for the 2013-2015 tax years also proposed to reduce Perrigo U.S.'s deductible interest expense for the 2014 tax year and the 2015 tax year on $7.5 billion in debts owed by it to Perrigo Company plc. The debts were incurred in connection with the Elan merger transaction in 2013. On May 7, 2020, the IRS issued a NOPA capping the interest rate on the debts for U.S. federal tax purposes at 130.0% of the Applicable Federal Rate ("AFR") (a blended rate reduction of 4.0% per annum), on the stated ground that the loans were not negotiated on an arms’-length basis. The NOPA proposes a reduction in gross interest expense of approximately $414.7 million for tax years 2014 and 2015. On January 13, 2021, we received a Revenue Agent Report ("RAR"), together with the 30-day letter, requiring our filing of a written Protest to request IRS Appeals consideration. The Protest was filed with the IRS on February 26, 2021. On May 3, 2021, the IRS notified us that it will no longer pursue the 130% of AFR position reflected in its NOPA due to a change in IRS policy. The IRS will provide a new proposed adjustment in its rebuttal to our Protest, which we have not yet received. Because the IRS' revised adjustment is currently unknown and cannot be quantified, we are unable to determine the amount of gross interest expense that the IRS proposes to disallow, and we cannot estimate any increase in tax expense attributable to any such disallowance for the period under audit. In addition, we expect the IRS to seek similar revised adjustments for the tax years ended December 31, 2015 through December 31, 2018 with potential section 163(j) carryover impacts beyond December 2018. We cannot determine the amount, if any, of the estimated increase in tax expense attributable to any such adjustments. No further interest adjustments are expected beyond this period. We strongly disagree with the IRS position and we will pursue all available administrative and judicial remedies necessary. At this stage, we are unable to estimate any additional liability associated with this matter. In addition, the 30-day letter for the 2013-2015 tax years expanded on a NOPA issued on December 11, 2019 and proposed to disallow adjustments to gross sales income on the sale of prescription products to wholesalers for accrued wholesale customer pipeline chargebacks where the prescription products were not re-sold by such wholesalers to covered retailers by the end of the tax year for the 2013-2015 tax years. The IRS' NOPA asserts that the reduction of gross sales income of such chargebacks is an impermissible method of accounting. The IRS proposed a change in accounting method that would defer the reduction in gross sales income until the year the prescription products were re-sold to covered retailers. The NOPA proposes an increase in sales revenue of approximately $99.5 million for the 2013-2015 tax years. We filed a protest on February 26, 2021 to request IRS Appeals consideration. If the IRS were to prevail in its proposed adjustment, we estimate a payment of approximately $18.0 million, excluding interest and penalties for the 2013-2015 tax years. In addition, we expect the IRS to seek similar adjustments for future years. If those future adjustments were to be sustained, based on preliminary calculations and subject to further analysis, our current best estimate is a payment that will not exceed $7.0 million through tax year ended December 31, 2020, excluding interest and penalties. We have fully reserved for this issue. We strongly disagree with the IRS’s proposed adjustment and will pursue all available administrative and judicial remedies necessary. Internal Revenue Service Audit of Athena Neurosciences, Inc., a U.S. Subsidiary On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena Neurosciences, Inc. ("Athena") for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. The NOPA carries forward the IRS's theory from its 2017 draft NOPA that when Elan took over the future funding of Athena's in-process research and development after acquiring Athena in 1996, Elan should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and any potential interest that may be imposed. We strongly disagree with the IRS position. On December 22, 2016, we also received a NOPA for these years denying the deductibility of settlement costs related to illegal marketing of Zonegran in the United States raised in a Qui Tam action. We strongly disagree with the IRS' position on this issue as well. Because we believe that any concession on these issues in Appeals would be contrary to our evaluation of the issues, we pursued our remedies under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. On April 14, 2020, we filed a request for Competent Authority Assistance with the IRS on the royalty issue, and it was accepted. On October 20, 2020, we amended our request for Competent Authority Assistance to include the Zonegran issue and this amendment was also accepted. On May 6, 2021, we had our opening conference with the IRS and discussed our submission, which continues to be reviewed by the IRS. Our opening conference with Irish Revenue is scheduled for July 23, 2021. No payment of the additional amounts is required until these two matters are resolved with finality under the treaty, or any additional administrative or judicial process if treaty negotiations are unsuccessful. Irish Revenue Audit of Fiscal Years Ended December 31, 2012 and December 31, 2013 On October 30, 2018, we received an audit findings letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the tax years ended December 31, 2012 and December 31, 2013. The audit findings letter relates to the tax treatment of the 2013 sale of the Tysabri ® intellectual property and related assets to Biogen Idec by Elan Pharma. The consideration paid by Biogen Idec to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Elan Pharma recognized such receipts as trading income in its tax returns filed with Irish Revenue, consistent with Elan Pharma's historical practice relating to its active management of intellectual property rights. In its audit findings letter, Irish Revenue proposed to charge Elan Pharma tax on the net chargeable gain realized by Elan Pharma on the Tysabri ® transaction in 2013 at a rate of 33%, rather than the 12.5% tax rate applied to trading income. On November 29, 2018, Irish Revenue issued a Notice of Amended Assessment (“NoA”) for the tax year ended December 31, 2013, in the amount of €1,643 million, and claiming tax payable in the amount of €1,636 million, not including any interest or applicable penalties. We strongly disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We will pursue all available administrative and judicial avenues as may be necessary or appropriate. Accordingly, we filed an appeal of the NoA on December 27, 2018 with the Irish Tax Appeals Commission ("TAC") which is the statutory body charged with considering whether the NoA is properly founded as a matter of Irish tax law. Separately, we were also granted leave by the Irish High Court on February 25, 2019 to seek judicial review of the issuance of the NoA by Irish Revenue. On November 4, 2020, the High Court ruled that the Irish Revenue's decision to issue the NoA did not violate Elan Pharma's constitutional rights and legitimate expectations as a taxpayer. Importantly, the Irish High Court did not rule on the merits of the NoA under Irish tax law. The TAC will now consider whether the NoA is correct as a matter of Irish tax law. The tax appeal is scheduled to be heard in November 2021. We strongly believe that Elan Pharma’s tax position is correct and would ultimately be confirmed through judicial process. However, in light of the risks and delays inherent in any litigation, representatives of Perrigo met with representatives of Irish Revenue on March 18, 2021 and April 14, 2021, to explore whether there may be a path forward toward resolving the dispute. On April 26, 2021, Perrigo, through its tax adviser, made a without prejudice written offer of settlement to Irish Revenue detailing a possible framework for such a resolution, which applied an alternative basis of taxation than the respective positions taken by Irish Revenue in the NoA and by Elan Pharma in its tax returns. On May 11, 2021, a representative of Irish Revenue verbally indicated to Perrigo's tax adviser that the written settlement offer would not be accepted as presented and that a formal response would be transmitted in due course. Perrigo will review Irish Revenue's formal response to Perrigo's offer when received and expects further discussions and correspondence with Irish Revenue prior to the TAC hearing in November. There can be no assurances that any settlement is possible on terms acceptable to Perrigo. Unless and until a final settlement is reached, Elan Pharma will vigorously pursue its tax appeal before the TAC, concurrently with any settlement discussions that may occur. No payment of any additional tax will be required unless and until required by a settlement or other final determination. Israel Tax Authority Audit of Fiscal Year Ended June 27, 2015 and Calendar Years Ended December 31, 2015 through December 31, 2017 The Israel Tax Authority audited our income tax returns for the 2015 tax year, and calendar years ended December 31, 2015, December 31, 2016 and December 31, 2017. On December 29, 2020, we received a Stage A assessment from the Israeli Tax Authority for the tax years ended December 31, 2015 through December 31, 2017 in the amount of $63.8 million relating to attribution of intangible income to Israel, income qualifying for a lower preferential rate of tax, exemption from capital gains tax, and deduction of certain settlement payments. Our protest was timely filed on March 11, 2021 to move the matter to Stage B of the assessment process. We strongly disagree with the assessment and will pursue all available administrative and judicial remedies necessary. Although we believe that our tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit and any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results and/or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments. Based on the final resolution of tax examinations, judicial or administrative proceedings, changes in facts or law, expirations of statute of limitations in specific jurisdictions or other resolutions of, or changes in, tax positions - one or more of which may occur within the next twelve months - it is reasonably possible that unrecognized tax benefits for certain tax positions taken on previously filed tax returns may change materially from those recorded as of April 3, 2021. However, we are not able to estimate a reasonably possible range of how these events may impact our unrecognized tax benefits in the next twelve months.

Contingencies

Contingencies	3 Months Ended
	Apr. 03, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of April 3, 2021, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations, or cash flows. Price-Fixing Lawsuits Perrigo is a defendant in several cases in the generic pricing multidistrict litigation MDL No. 2724 (United States District Court for Eastern District of Pennsylvania) . This multidistrict litigation, which has many cases that do not include Perrigo, includes class action and opt-out cases for federal and state antitrust claims, as well as complaints filed by certain states alleging violations of state antitrust laws. On July 14, 2020, the court issued an order designating the following cases to proceed on a more expedited basis (as a bellwether) than the other cases in MDL No. 2724: (a) the May 2019 state case alleging an overarching conspiracy involving more than 120 products (which does not name Perrigo a defendant) and (b) class actions alleging “single drug” conspiracies involving Clomipramine, Pravastatin, and Clobetasol. Perrigo is a defendant in the Clobetasol cases but not the others. On February 9, 2021, the court entered an order provisionally deciding to remove the May 2019 state case and the pravastatin class cases from the bellwether proceedings. On May 7, 2021, the Court ruled that the clobetasol end payer and direct purchaser class cases will remain part of the bellwether. The Court also ruled that the June 10, 2020 State Complaint against Perrigo and approximately 35 other manufacturers will move forward as a bellwether case. No schedule has been set for the bellwether cases. Class Action Complaints (a) Single Drug Conspiracy Class Actions We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging single-product conspiracies to fix or raise the prices of certain drugs and/or allocate customers for those products starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The court denied motions to dismiss each of the complaints alleging “single drug” conspiracies involving Perrigo, and the cases are proceeding in discovery. As noted above, the Clobetasol cases have been designated to proceed on a more expedited schedule than the other cases. That schedule has not yet been set. (b) “Overarching Conspiracy” Class Actions The same three putative classes, including (a) direct purchasers, (b) end payors, and (c) indirect resellers, have filed two sets of class action complaints alleging that Perrigo and other manufacturers (and some individuals) entered into an “overarching conspiracy” that involved allocating customers, rigging bids and raising, maintaining, and fixing prices for various products. Each class brings claims for violations of Sections 1 and 3 of the Sherman Antitrust Act as well as several state antitrust and consumer protection statutes. Filed in June 2018, and later amended in December 2018 (with respect to direct purchasers) and April 2019 (with respect to end payors and indirect resellers), the first set of “overarching conspiracy” class actions include allegations against Perrigo and approximately 27 other manufacturers involving 135 drugs with allegations dating back to March 2011. The allegations against Perrigo concern only two formulations (cream and ointment) of one of the products at issue, Nystatin. The court denied motions to dismiss the first set of “overarching conspiracy” class actions, and they are proceeding in discovery. None of these cases are included in the group of cases on a more expedited schedule pursuant to the court’s July 14, 2020 order. In December 2019, both the end payor and indirect reseller class plaintiffs filed a second set of "overarching conspiracy” class actions against Perrigo, dozens of other manufacturers of generic prescription pharmaceuticals, and certain individuals dating back to July 2009 (end payors) or January 2010 (indirect resellers). The direct purchaser plaintiffs filed their second round overarching conspiracy complaint in February 2020 with claims dating back to July 2009. On March 11, 2020, the indirect reseller plaintiffs filed a motion to amend their second round December 2019 complaint, and that motion was granted. On September 4, 2020, and December 15, 2020, the end payor plaintiffs amended their second round complaint. On October 21, 2020, the direct purchaser plaintiffs amended their second round complaint. On December 15, 2020, the indirect reseller plaintiffs filed another complaint adding allegations for additional drugs that mirror the other class plaintiffs’ claims. This second set of overarching complaints allege conspiracies relating to the sale of various products that are not at issue in the earlier-filed overarching conspiracy class actions, the majority of which Perrigo neither makes nor sells. The amended indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Betamethasone Dipropionate lotion, Imiquimod cream, Desonide cream and ointment, and Hydrocortisone Valerate cream. The December 2020 indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Adapalene, Ammonium Lactate, Bromocriptine Mesylate, Calcipotriene, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Methazolamide, Mometasone Furoate, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended end payor complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended direct purchaser complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Proprionate, Hydrocortisone Valerate, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. Perrigo has not yet responded to the second set of overarching conspiracy complaints, and responses are currently or will be stayed. Opt-Out Complaints On January 22, 2018, Perrigo was named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. On December 21, 2018, an amended complaint was filed that adds additional products and allegations against a total of 39 manufacturers for 33 products. The only allegations specific to Perrigo relate to Clobetasol, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo moved to dismiss this complaint on February 21, 2019. The motion was denied on August 15, 2019. The case is proceeding in discovery. On February 3, 2020, the plaintiffs requested leave to file a second amended complaint. The proposed amended complaint adds dozens of additional products and allegations to the original complaint. Perrigo is discussed in connection with allegations concerning an additional drug, Fenofibrate. Defendants opposed the motion for leave to file a second amended complaint and the court has yet to rule on the issue. On August 3, 2018, a large managed care organization filed a complaint alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to Perrigo concern Clobetasol. Perrigo moved to dismiss this complaint on February 21, 2019. Plaintiff filed a second amended complaint in April 2019 that adds additional products and allegations. The amended allegations that concern Perrigo include: Clobetasol, Desonide, Econazole, and Nystatin. The motion to dismiss was denied on August 15, 2019. The case is proceeding in discovery. The same organization amended a different complaint that it had filed in October 2019, which did not name Perrigo, on December 15, 2020, adding Perrigo as a defendant and asserting new allegations of alleged antitrust violations involving Perrigo and dozens of other generic pharmaceutical manufacturers. The allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Proprionate, Hydrocortisone Valerate, Imiquimod, Permethrin, Prochlorperazine Maleate, and Triamcinolone Acetonide. The same organization filed a third complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Ammonium Lactate, Calcipotriene Betamethasone Dipropionate, Erythromycin, Fluticasone Propionate, Hydrocortisone Acetate, Methazolamide, Promethazine HCL, and Tacrolimus. On January 16, 2019, a health insurance carrier filed a complaint in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to Perrigo concerned Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations that concern Perrigo relate to Fluocinonide. The same health insurance carrier filed a new complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On July 18, 2019, 87 health plans filed a Praecipe to Issue Writ of Summons in Pennsylvania state court to commence an action against 53 generic pharmaceutical manufacturers and 17 individuals, alleging antitrust violations concerning generic pharmaceutical drugs. While Perrigo was named as a defendant, no complaint has been filed and the precise allegations and products at issue have not been identified. Proceedings in the case, including the filing of a complaint, have been stayed at the request of the plaintiffs. On December 11, 2019, a health care service company filed a complaint against Perrigo and 38 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other multi-district litigation ("MDL") complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream/ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On December 16, 2019, a Medicare Advantage claims recovery company filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, and Econazole. The complaint was originally filed in the District of Connecticut but has been consolidated into the MDL. Perrigo has not yet had the opportunity to respond to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desoximetasone, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On December 23, 2019, several counties in New York filed an amended complaint against Perrigo and 28 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was originally filed in New York State court but was removed to federal court and has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On December 27, 2019, a healthcare management organization filed a complaint against Perrigo and 25 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed originally in the Northern District of California but has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On March 1, 2020, Harris County of Texas filed a complaint against Perrigo and 29 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene, Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Ethinyl Estradiol/Levonorgestrel, Fenofibrate, Fluocinolone, Fluocinonide, Gentamicin, Glimepiride, Griseofulvin, Halobetasol Propionate, Hydrocortisone Valerate, Ketoconazole, Mupirocin, Nystatin, Olopatadine, Permethrin, Prednisone, Promethazine, Scopolamine, and Triamcinolone Acetonide. The complaint was originally filed in the Southern District of Texas but has been transferred to the MDL. Harris County amended its complaint in May 2020. Perrigo has not yet responded to the complaint, and responses are currently stayed. In May 2020, seven health plans filed a writ of summons in the Pennsylvania Court of Common Pleas in Philadelphia concerning an as-yet unfiled complaint against Perrigo, three dozen other manufacturers, and seventeen individuals, concerning alleged antitrust violations in connection with the pricing and sale of generic prescription pharmaceutical products. No complaint has yet been filed, so the precise allegations and products at issue are not yet clear. In addition, Defendants are in the process of being served, and proceedings in the case will likely be stayed. On June 9, 2020, a health insurance carrier filed a complaint against Perrigo and 25 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On July 9, 2020, a drugstore chain filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. Perrigo is also listed in connection with Fenofibrate. The complaint was filed in the Eastern District of Pennsylvania and will be transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On August 27, 2020, Suffolk County of New York filed a complaint against Perrigo and 35 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream and ointment. The other products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene gel, Albuterol, Benazepril HCTZ, Clotrimazole, Diclofenac Sodium, Fenofibrate, Fluocinonide, Glimepiride, Ketoconazole, Meprobamate, Imiquimod, Triamcinolone Acetonide, Erythromycin/Ethyl Solution, Betamethasone Valerate, Ciclopirox Olamine, Terconazole, Hydrocortisone Valerate, Fluticasone Propionate, Desoximetasone, Clindamycin Phosphate, Halobetasol Propionate, Hydrocortisone Acetate, Promethazine HCL, Mometasone Furoate, and Amiloride HCTZ. The complaint was filed in the Eastern District of New York and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On September 4, 2020, a drug wholesaler and distributor filed a complaint against Perrigo and 39 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone furoate, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and will be transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 11, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Permethrin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and will be transferred into the MDL. On December 14, 2020, a supermarket chain filed a complaint against Perrigo and 45 other manufacturers (as well as certain individuals) alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Fenofibrate, Halobetasol, Hydrocortisone Valerate, Nystatin, Permethrin, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. On December 15, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The complaint lists 63 drugs that the chain purchased from Perrigo, but the product conspiracies allegedly involving Perrigo focus on Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desonide, Econazole, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. On December 15, 2020, several counties in New York filed a complaint against Perrigo and 45 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The allegations that concern Perrigo include: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Proprionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was originally filed in New York State court but has been removed to federal court and consolidated into the MDL. State Attorney General Complaint On June 10, 2020, the Connecticut Attorney General’s office filed a lawsuit on behalf of Connecticut and 50 other states and territories against Perrigo, 35 other generic pharmaceutical manufacturers, and certain individuals (including one former and one current Perrigo employee), alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of eighty products. The allegations against Perrigo focus on the following drugs: Adapalene Cream, Ammonium Lactate cream and lotion, Betamethasone dipropionate lotion, Bromocriptine tablets, Calcipotriene Betamethasone Dipropionate Ointment, Ciclopirox cream and solution, Clindamycin solution, Desonide cream and ointment, Econazole cream, Erythromycin base alcohol solution, Fluticasone cream and lotion, Halobetasol cream and ointment, Hydrocortisone Acetate suppositories, Hydrocortisone Valerate cream, Imiquimod cream, Methazolamide tablets, Nystatin ointment, Prochlorperazine suppositories, Promethazine HCL suppositories, Tacrolimus ointment, and Triamcinolone cream and ointment. The Complaint was filed in the District of Connecticut, but has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. Canadian Class Action Complaint In June 2020, an end payor filed a class action in Ontario, Canada against Perrigo and 29 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. In December 2020, Plaintiffs amended their complaint to add additional claims based on the State AG complaint of June 2020. On May 7, 2021, the Court ruled that this case will move forward as a bellwether case. Perrigo has not yet responded to the complaint, and no schedule has been set for such responses. At this stage, we cannot reasonably estimate the outcome of the liability if any, associated with the claims listed above. Securities Litigation In the United States (cases related to events in 2015-2017) On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey ( Roofers’ Pension Fund v. Papa, et al. ). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey ( Wilson v. Papa, et al. ). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order. On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders: (i) shareholders who purchased shares during the period from April 21, 2015 through May 3, 2017 on the U.S. exchanges; (ii) shareholders who purchased shares during the same period on the Tel Aviv exchange; and (iii) shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares. The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri ® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims

Restructuring Charges

Restructuring Charges	3 Months Ended
	Apr. 03, 2021
Restructuring Charges [Abstract]
Restructuring Charges	RESTRUCTURING CHARGES We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and related consulting fees. The following reflects our restructuring activity (in millions): Three Months Ended April 3, March 28, Beginning balance $ 9.1 $ 19.5 Additional charges 1.8 — Payments (4.4) (3.5) Non-cash adjustments (0.3) — Ending balance $ 6.2 $ 16.0 The charges incurred during the three months ended April 3, 2021 were primarily associated with actions taken to streamline the organization. There were no charges incurred during the three months ended March 28, 2020. There were no other material restructuring programs for the three months ended April 3, 2021. All charges are recorded in Restructuring expense on the Condensed Consolidated Statements of Operations. The remaining $6.2 million liability for employee severance benefits is expected to be paid within the next year.

Segment Information

Segment Information	3 Months Ended
	Apr. 03, 2021
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. As discussed in Note 8 , as of March 1, 2021, the financial results and assets and liabilities of the RX business are classified as discontinued operations in the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets. The RX business assets held-for-sale are included below in the summary of total assets. The tables below show select financial measures by reporting segment (in millions): Total Assets April 3, December 31, CSCA $ 4,738.9 $ 4,585.1 CSCI 4,596.8 4,872.4 Held-for-sale 1,989.1 2,030.9 Total $ 11,324.8 $ 11,488.4 Three Months Ended April 3, 2021 March 28, 2020 Net Operating Income (Loss) Intangible Asset Amortization Net Operating Income (Loss) Intangible Asset Amortization CSCA $ 640.5 $ 95.6 $ 12.9 $ 700.6 $ 122.1 $ 14.3 CSCI 369.5 17.4 40.3 382.7 25.0 38.3 Unallocated — (61.6) — — (60.7) — Continuing Operations Total $ 1,010.0 $ 51.4 $ 53.2 $ 1,083.3 $ 86.4 $ 52.6

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 03, 2021
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation    The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020.
Principles of consolidation	In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business ("RX business") to Altaris Capital Partners, LLC ("Altaris"). The financial results of our RX business, which were previously reported in our Prescription Pharmaceuticals ("RX") segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of our RX business are reflected as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets for all periods presented. Refer to Note 8 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Condensed Consolidated Financial Statements relate to our continuing operations.
Segment Reporting	Segment Reporting Our reporting and operating segments are as follows: • Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada. • Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020.
Reclassifications
Recently Issued Accounting Standards	Allowance for Credit Losses Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and for reasonable and supportable forecasts. Historical credit loss experience provides the primary basis for estimation of expected credit losses. Adjustments to historical loss information may be made for significant changes in a geographic location’s economic conditions. Receivables that do not share risk characteristics are evaluated on an individual basis. These receivables are not included in the collective evaluation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Apr. 03, 2021
Accounting Policies [Abstract]
Allowance for Credit Losses	The following table presents the allowance for credit losses activity (in millions): Three Months Ended April 3, March 28, Beginning balance $ 6.5 $ 6.0 Provision for credit losses, net 2.9 0.4 Receivables written-off — — Recoveries collected (0.2) — Currency translation adjustment (0.1) (0.2) Ending balance $ 9.1 $ 6.2

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Apr. 03, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	We generated net sales in the following geographic locations (1) (in millions): Three Months Ended April 3, March 28, U.S. $ 611.3 $ 670.7 Europe (2) 355.3 372.6 All other countries (3) 43.4 40.0 Total net sales $ 1,010.0 $ 1,083.3 (1) Derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $4.5 million and $3.8 million for the three months ended April 3, 2021, and March 28, 2020, respectively. (3) Includes net sales generated primarily in Mexico, Australia and Canada. Product Category The following is a summary of our net sales by category (in millions): Three Months Ended April 3, March 28, CSCA (1) Upper respiratory $ 114.0 $ 154.6 Digestive health 113.5 106.9 Pain and sleep-aids 92.4 120.4 Nutrition 92.0 102.2 Healthy lifestyle 75.5 85.8 Oral self-care 73.7 55.3 Skincare and personal hygiene 53.3 46.7 Vitamins, minerals, and supplements 7.8 6.4 Other CSCA (2) 18.3 22.3 Total CSCA 640.5 700.6 CSCI Skincare and personal hygiene 107.0 94.7 Vitamins, minerals, and supplements 59.0 48.5 Healthy lifestyle 50.3 43.6 Pain and sleep-aids 49.0 46.8 Upper respiratory 42.9 84.1 Oral self-care 25.5 23.2 Digestive health 8.5 6.0 Other CSCI (3) 27.3 35.8 Total CSCI 369.5 382.7 Total net sales $ 1,010.0 $ 1,083.3 (1) Includes net sales from our OTC contract manufacturing business. (2) Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales. (3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances	The following table provides information about contract assets from contracts with customers (in millions): Balance Sheet Location April 3, December 31, Short-term contract assets Prepaid expenses and other current assets $ 18.4 $ 19.7

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Apr. 03, 2021
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	The following table presents unaudited pro forma information as if the acquisitions of Dr. Fresh and the Eastern European Brands occurred on January 1, 2019, and had been combined with the results reported in our Condensed Consolidated Statements of Operations for all periods presented (in millions): Three Months Ended (Unaudited) March 28, Net sales $ 1,119.1 Income from continuing operations $ 62.6
Oral Care Assets of High Ridge Brands (Dr. Fresh)
Business Acquisition [Line Items]
Schedule of Assets Acquired and Liabilities Assumed	The following table summarizes the consideration paid for Dr. Fresh and the amounts of the assets acquired and liabilities assumed (in millions): Oral Care Assets of High Ridge Brands (Dr. Fresh) Purchase price paid $ 106.2 Assets acquired: Accounts receivable 13.1 Inventories 22.2 Prepaid expenses and other current assets 0.4 Property, plant and equipment, net 0.7 Operating lease assets 2.6 Goodwill 17.2 Distribution and license agreements and supply agreements $ 2.2 Developed product technology, formulations, and product rights 0.1 Customer relationships and distribution networks 20.6 Trademarks, trade names, and brands 43.2 Total intangible assets $ 66.1 Total assets $ 122.3 Liabilities assumed: Accounts payable $ 6.1 Other accrued liabilities 3.8 Payroll and related taxes 0.7 Accrued customer programs 3.0 Other non-current liabilities 2.5 Total liabilities $ 16.1 Net assets acquired $ 106.2

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Apr. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): December 31, Purchase accounting adjustments Currency translation adjustments April 3, CSCA $ 1,905.0 $ 2.4 $ (1.9) $ 1,905.5 CSCI (1) 1,190.7 (2.4) (41.5) 1,146.8 Total goodwill $ 3,095.7 $ — $ (43.4) $ 3,052.3 (1) We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and April 3, 2021.
Schedule of Finite and Indefinite-lived Intangible Assets	Intangible assets and related accumulated amortization consisted of the following (in millions): April 3, 2021 December 31, 2020 Gross Accumulated Gross Accumulated Indefinite-lived intangibles: Trademarks, trade names, and brands $ 4.3 $ — $ 4.3 $ — In-process research and development 2.7 — 2.7 — Total indefinite-lived intangibles $ 7.0 $ — $ 7.0 $ — Definite-lived intangibles: Distribution and license agreements and supply agreements $ 73.2 $ 55.1 $ 74.8 $ 55.4 Developed product technology, formulations, and product rights 301.8 180.5 303.3 177.3 Customer relationships and distribution networks 1,873.9 830.9 1,920.5 823.7 Trademarks, trade names, and brands 1,534.4 350.5 1,581.5 342.2 Non-compete agreements 2.4 2.4 2.9 2.9 Total definite-lived intangibles $ 3,785.7 $ 1,419.4 $ 3,883.0 $ 1,401.5 Total intangible assets $ 3,792.7 $ 1,419.4 $ 3,890.0 $ 1,401.5

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 03, 2021
Inventory Disclosure [Abstract]
Major Components of Inventory	Major components of inventory were as follows (in millions): April 3, December 31, Finished goods $ 648.2 $ 574.1 Work in process 234.7 220.4 Raw materials 253.2 264.9 Total inventories $ 1,136.1 $ 1,059.4

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis	The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions): April 3, 2021 December 31, 2020 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Measured at fair value on a recurring basis: Assets: Investment securities $ 2.9 $ — $ — $ 2.5 $ — $ — Foreign currency forward contracts — 7.2 — — 9.8 — Cross-currency swap — 5.7 — — 6.3 — Total assets $ 2.9 $ 12.9 $ — $ 2.5 $ 16.1 $ — Liabilities: Foreign currency forward contracts $ — $ 6.5 $ — $ — $ 7.9 $ — Total liabilities $ — $ 6.5 $ — $ — $ 7.9 $ —
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions): Three Months Ended March 28, Beginning balance $ 95.3 Change in fair value 1.6 Ending balance $ 96.9
Schedule of Fair Value Assumptions	The table below represents the volatility and rate of return: Three Months Ended March 28, Volatility 35.0 % Rate of return 7.29 %
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments	Our fixed rate long-term debt consisted of the following (in millions): April 3, December 31, Level 1 Level 2 Level 1 Level 2 Public Bonds Carrying Value (excluding discount) $ 2,760.0 $ — $ 2,760.0 $ — Fair value $ 2,863.7 $ — $ 3,031.1 $ — Private placement note Carrying value (excluding premium) $ — $ 158.8 $ — $ 164.9 Fair value $ — $ 176.6 $ — $ 177.5

Investments (Tables)

Investments (Tables)	3 Months Ended
	Apr. 03, 2021
Investments [Abstract]
Equity Securities	The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions): Measurement Category Balance Sheet Location April 3, December 31, Fair value method Prepaid expenses and other current assets $ 2.9 $ 2.5 Fair value method (1) Other non-current assets $ 1.5 $ 1.9 Equity method Other non-current assets $ 69.1 $ 69.8 (1) Measured at fair value using the Net Asset Value practical expedient.
Equity Security Expense (Income)	The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions): Three Months Ended Measurement Category Income Statement Location April 3, March 28, Fair value method Other (income) expense, net $ — $ 2.9 Equity method Other (income) expense, net $ 0.7 $ (0.7)

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Apr. 03, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontined Operations - Financial Statement Information	Income from discontinued operations, net of tax was as follows (in millions): Three Months Ended April 3, March 28, Net sales $ 200.1 $ 257.7 Cost of sales 138.3 165.8 Gross profit 61.8 91.9 Operating expenses Distribution 3.3 4.0 Research and development 13.4 13.6 Selling 7.4 7.3 Administration 18.2 6.5 Other operating expense (income) (0.9) 1.1 Total operating expenses 41.4 32.5 Operating income $ 20.4 $ 59.4 Interest expense, net 0.6 1.4 Other (income) expense, net (1.5) 0.7 Income before income taxes 21.3 57.3 Income tax expense (benefit) (14.0) 8.5 Income from discontinued operations, net of tax $ 35.3 $ 48.8 During the three months ended April 3, 2021, we incurred $9.3 million of separation costs related to the sale of the RX business, which are recorded in administration expenses. Select cash flow information related to discontinued operations was as follows (in millions): Three Months Ended April 3, March 28, Cash flows from discontinued operations operating activities: Depreciation and amortization $ 15.3 $ 24.0 Cash flows from discontinued operations investing activities: Asset acquisitions $ (69.7) $ (0.1) Additions to property, plant and equipment $ (3.2) $ (2.9) The assets and liabilities classified as held for sale were as follows (in millions): April 3, December 31, Cash and cash equivalents $ 9.6 $ 10.0 Accounts receivable, net of allowance for credit losses of $1.1 and $1.1, respectively 419.9 460.7 Inventories 136.8 140.8 Prepaid expenses and other current assets 29.7 55.4 Current assets held for sale* 666.9 Property, plant and equipment, net 126.4 131.4 Operating lease assets 29.6 31.3 Goodwill and indefinite-lived intangible assets 678.7 681.2 Definite-lived intangible assets, net 533.0 492.8 Deferred income taxes 3.0 3.6 Other non-current assets 22.4 23.7 Non-current assets held for sale* 1,364.0 Total assets held for sale $ 1,989.1 $ 2,030.9 Accounts payable $ 101.1 $ 92.2 Payroll and related taxes 16.7 22.3 Accrued customer programs 185.9 237.4 Other accrued liabilities 47.4 67.2 Current indebtedness 0.5 0.5 Current liabilities held for sale* 419.6 Long-term debt, less current portion 0.6 0.7 Deferred income taxes 2.9 3.1 Other non-current liabilities 94.9 104.5 Non-current liabilities held for sale* 108.3 Total liabilities held for sale $ 450.0 $ 527.9

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	3 Months Ended
	Apr. 03, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Foreign Currency Forward Contracts	Foreign currency forward contracts were as follows (in millions): Notional Amount April 3, December 31, European Euro (EUR) $ 270.7 $ 312.6 Israeli Shekel (ILS) 74.1 94.4 United States Dollar (USD) 63.4 101.5 Chinese Yuan (CNY) 50.4 49.1 British Pound (GBP) 44.8 92.3 Danish Krone (DKK) 44.0 65.2 Swedish Krona (SEK) 30.1 41.2 Canadian Dollar (CAD) 27.8 36.8 Polish Zloty (PLZ) 18.3 21.8 Mexican Peso (MPX) 14.8 15.6 Norwegian Krone (NOK) 9.7 7.8 Australian Dollar (AUD) 9.1 11.3 Romanian New Leu (RON) 4.8 3.6 Switzerland Franc (CHF) 4.6 8.2 Turkish Lira (TRY) 3.7 4.0 Other 2.4 2.3 Total $ 672.7 $ 867.7
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions): Asset Derivatives Fair Value Balance Sheet Location April 3, December 31, Designated derivatives: Foreign currency forward contracts Prepaid expenses and other current assets $ 5.6 $ 5.0 Foreign currency forward contracts Other non-current assets 0.4 0.5 Cross-currency swap Other non-current assets 5.7 6.3 Total designated derivatives $ 11.7 $ 11.8 Non-designated derivatives: Foreign currency forward contracts Prepaid expenses and other current assets $ 1.2 $ 4.3 Liability Derivatives Fair Value Balance Sheet Location April 3, December 31, Designated derivatives: Foreign currency forward contracts Other accrued liabilities $ 3.6 $ 5.5 Non-designated derivatives: Foreign currency forward contracts Other accrued liabilities $ 2.9 $ 2.4
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The following tables summarize the effect of derivative instruments designated as hedging instruments in Accumulated Other Comprehensive Income ("AOCI") (in millions): Three Months Ended April 3, 2021 Instrument Amount of Gain/(Loss) Recorded in OCI (1) Classification of Gain/(Loss) Reclassified from AOCI into Earnings Amount of Gain/(Loss) Reclassified from AOCI into Earnings Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing Cash flow hedges: Interest rate swap agreements $ — Interest expense, net $ (0.5) Interest expense, net $ — Foreign currency forward contracts 1.7 Net sales (0.9) Net sales — Cost of sales (1.4) Cost of sales 0.1 Other (income) expense, net (0.1) $ 1.7 $ (2.8) $ — Net investment hedges: Cross-currency swap $ (0.5) Interest expense, net $ 1.0 (1) Net loss of $13.4 million is expected to be reclassified out of AOCI into earnings during the next 12 months. Three Months Ended March 28, 2020 Instrument Amount of Gain/(Loss) Recorded in OCI Classification of Gain/(Loss) Reclassified from AOCI into Earnings Amount of Gain/(Loss) Reclassified from AOCI into Earnings Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing Cash flow hedges: Interest rate swap agreements $ — Interest expense, net $ (0.5) Interest expense, net $ — Foreign currency forward contracts 9.3 Net sales (0.4) Net sales — Cost of sales (1.0) Cost of sales 0.4 $ 9.3 $ (1.9) $ 0.4 Net investment hedges: Cross-currency swap $ (15.0) Interest expense, net $ 2.8
Amount of Gain/(Loss) Recognized against Earnings	The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions): Three Months Ended Non-Designated Derivatives Income Statement April 3, March 28, Foreign currency forward contracts Other (income) expense, net $ (4.8) $ 6.2 Interest expense, net 1.2 0.9 $ (3.6) $ 7.1
Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships	The classification and amount of gain/(loss) recognized in earnings on fair value and hedging relationships were as follows (in millions): Three Months Ended April 3, 2021 Net Sales Cost of Sales Interest Expense, net Other (Income) Expense, net Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded $ 1,010.0 $ 641.6 $ 32.0 $ 2.4 The effects of cash flow hedging: Gain (loss) on cash flow hedging relationships Foreign currency forward contracts Amount of gain or (loss) reclassified from AOCI into earnings $ (0.9) $ (1.4) $ — $ — Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach $ — $ 0.1 $ — $ (0.1) Interest rate swap agreements Amount of gain or (loss) reclassified from AOCI into earnings $ — $ — $ (0.5) $ — Three Months Ended March 28, 2020 Net Sales Cost of Sales Interest Expense, net Other (Income) Expense, net Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded $ 1,083.3 $ 689.6 $ 28.9 $ 1.7 The effects of cash flow hedging: Gain (loss) on cash flow hedging relationships Foreign currency forward contracts Amount of gain or (loss) reclassified from AOCI into earnings $ (0.4) $ (1.0) $ — $ — Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach $ — $ 0.4 $ — $ — Interest rate swap agreements Amount of gain or (loss) reclassified from AOCI into earnings $ — $ — $ (0.5) $ —

Leases (Tables)

Leases (Tables)	3 Months Ended
	Apr. 03, 2021
Leases [Abstract]
Balance Sheet Location of Lease Assets and Liabilities	The balance sheet locations of our lease assets and liabilities were as follows (in millions): Assets Balance Sheet Location April 3, December 31, Operating Operating lease assets $ 149.7 $ 154.7 Finance Other non-current assets 32.2 29.8 Total $ 181.9 $ 184.5 Liabilities Balance Sheet Location April 3, December 31, Current Operating Other accrued liabilities $ 27.1 $ 28.3 Finance Current indebtedness 5.2 6.7 Non-Current Operating Other non-current liabilities 128.2 132.5 Finance Long-term debt, less current portion 24.3 20.2 Total $ 184.8 $ 187.7 The below table shows our lease assets and liabilities by reporting segment (in millions): Assets Liabilities Operating Financing Operating Financing April 3, December 31, April 3, December 31, April 3, December 31, April 3, December 31, CSCA $ 74.2 $ 75.9 $ 16.3 $ 16.7 $ 73.9 $ 75.8 $ 16.7 $ 17.0 CSCI 32.9 34.4 8.7 5.9 33.7 35.2 5.5 2.5 Unallocated 42.6 44.4 7.2 7.2 47.7 49.8 7.3 7.4 Total $ 149.7 $ 154.7 $ 32.2 $ 29.8 $ 155.3 $ 160.8 $ 29.5 $ 26.9
Lease Expense	Lease expense was as follows (in millions): Three Months Ended April 3, March 28, Operating leases (1) $ 9.8 $ 9.6 Finance leases Amortization $ 1.5 $ 1.0 Interest 0.2 0.2 Total finance leases $ 1.7 $ 1.2 (1) Includes short-term leases and variable lease costs, which are immaterial.
Finance Lease Maturity	The annual future maturities of our leases as of April 3, 2021 are as follows (in millions): Operating Leases Finance Leases Total 2021 $ 24.0 $ 4.5 $ 28.5 2022 26.2 5.5 31.7 2023 18.9 3.8 22.7 2024 15.9 2.3 18.2 2025 13.9 2.2 16.1 After 2025 80.5 15.8 96.3 Total lease payments 179.4 34.1 213.5 Less: Interest 24.1 4.6 28.7 Present value of lease liabilities $ 155.3 $ 29.5 $ 184.8
Operating Lease Liability Maturity	The annual future maturities of our leases as of April 3, 2021 are as follows (in millions): Operating Leases Finance Leases Total 2021 $ 24.0 $ 4.5 $ 28.5 2022 26.2 5.5 31.7 2023 18.9 3.8 22.7 2024 15.9 2.3 18.2 2025 13.9 2.2 16.1 After 2025 80.5 15.8 96.3 Total lease payments 179.4 34.1 213.5 Less: Interest 24.1 4.6 28.7 Present value of lease liabilities $ 155.3 $ 29.5 $ 184.8
Weighted Average Lease Terms and Discount Rates	Our weighted average lease terms and discount rates are as follows: April 3, March 28, Weighted-average remaining lease term (in years) Operating leases 10.52 5.98 Finance leases 9.31 10.10 Weighted-average discount rate Operating leases 2.97 % 3.97 % Finance leases 2.76 % 3.42 %
Lease Cash Flow Classifications	Our lease cash flow classifications are as follows (in millions): Three Months Ended April 3, March 28, Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 10.0 $ 8.9 Operating cash flows for finance leases $ 0.2 $ 0.2 Financing cash flows for finance leases $ 1.3 $ 0.9 Leased assets obtained in exchange for new finance lease liabilities $ 4.2 $ 1.5 Leased assets obtained in exchange for new operating lease liabilities $ 3.9 $ 4.9

Indebtedness (Tables)

Indebtedness (Tables)	3 Months Ended
	Apr. 03, 2021
Debt Disclosure [Abstract]
Schedule of Debt	Total borrowings outstanding are summarized as follows (in millions): April 3, December 31, Term loan 2019 Term loan due August 15, 2022 $ 600.0 $ 600.0 Notes and Bonds Coupon Due 5.105% July 28, 2023 (1) 158.8 164.9 4.000% November 15, 2023 215.6 215.6 3.900% December 15, 2024 700.0 700.0 4.375% March 15, 2026 700.0 700.0 3.150% June 15, 2030 750.0 750.0 5.300% November 15, 2043 90.5 90.5 4.900% December 15, 2044 303.9 303.9 Total notes and bonds 2,918.8 2,924.9 Other financing 60.1 57.4 Unamortized premium (discount), net (1.5) (0.3) Deferred financing fees (16.3) (17.1) Total borrowings outstanding 3,561.1 3,564.9 Current indebtedness (35.8) (37.3) Total long-term debt less current portion $ 3,525.3 $ 3,527.6 (1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Earnings Per Share and Shareh_2

Earnings Per Share and Shareholders' Equity (Tables)	3 Months Ended
	Apr. 03, 2021
Earnings Per Share [Abstract]
Schedule of Earnings per Share, Basic and Diluted	A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): Three Months Ended April 3, March 28, Numerator: Income from continuing operations $ 2.8 $ 57.6 Income from discontinued operations, net of tax 35.3 48.8 Net income $ 38.1 $ 106.4 Denominator: Weighted average shares outstanding for basic EPS 133.2 136.2 Dilutive effect of share-based awards 1.4 1.1 Weighted average shares outstanding for diluted EPS 134.6 137.3 Anti-dilutive share-based awards excluded from computation of diluted EPS 1.8 1.7

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Apr. 03, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in our AOCI balances, net of tax were as follows (in millions): Fair Value of Derivative Financial Instruments, net of tax Foreign Currency Translation Adjustments Post-Retirement and Pension Liability Adjustments, net of tax Total AOCI Balance at December 31, 2020 $ (0.7) $ 407.3 $ (11.6) $ 395.0 OCI before reclassifications (8.8) (111.6) (0.7) (121.1) Amounts reclassified from AOCI 2.8 — — 2.8 Other comprehensive income (loss) $ (6.0) $ (111.6) $ (0.7) $ (118.3) Balance at April 3, 2021 $ (6.7) $ 295.7 $ (12.3) $ 276.7

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Apr. 03, 2021
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	The effective tax rates were as follows: Three Months Ended April 3, March 28, 84.0 % (0.4) %

Restructuring Charges (Tables)

Restructuring Charges (Tables)	3 Months Ended
	Apr. 03, 2021
Restructuring Charges [Abstract]
Restructuring and Related Costs	The following reflects our restructuring activity (in millions): Three Months Ended April 3, March 28, Beginning balance $ 9.1 $ 19.5 Additional charges 1.8 — Payments (4.4) (3.5) Non-cash adjustments (0.3) — Ending balance $ 6.2 $ 16.0

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Apr. 03, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The tables below show select financial measures by reporting segment (in millions): Total Assets April 3, December 31, CSCA $ 4,738.9 $ 4,585.1 CSCI 4,596.8 4,872.4 Held-for-sale 1,989.1 2,030.9 Total $ 11,324.8 $ 11,488.4 Three Months Ended April 3, 2021 March 28, 2020 Net Operating Income (Loss) Intangible Asset Amortization Net Operating Income (Loss) Intangible Asset Amortization CSCA $ 640.5 $ 95.6 $ 12.9 $ 700.6 $ 122.1 $ 14.3 CSCI 369.5 17.4 40.3 382.7 25.0 38.3 Unallocated — (61.6) — — (60.7) — Continuing Operations Total $ 1,010.0 $ 51.4 $ 53.2 $ 1,083.3 $ 86.4 $ 52.6

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Allowance for Credit Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 6.5	$ 6
Provision for credit losses, net	2.9	0.4
Receivables written-off	0	0
Recoveries collected	(0.2)	0
Currency translation adjustment	(0.1)	(0.2)
Ending balance	$ 9.1	$ 6.2

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenue by Geographic Location (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,010	$ 1,083.3
U.S.
Disaggregation of Revenue [Line Items]
Net sales	[1]	611.3	670.7
Europe
Disaggregation of Revenue [Line Items]
Net sales	[1],[2]	355.3	372.6
All other countries
Disaggregation of Revenue [Line Items]
Net sales	[1],[3]	43.4	40
Ireland
Disaggregation of Revenue [Line Items]
Net sales		$ 4.5	$ 3.8
[1]	Derived from the location of the entity that sells to a third party.
[2]	Includes Ireland net sales of $4.5 million and $3.8 million for the three months ended April 3, 2021, and March 28, 2020, respectively.
[3]	Includes net sales generated primarily in Mexico, Australia and Canada.

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,010	$ 1,083.3
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	640.5	700.6
CSCA | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	[2]	114	154.6
CSCA | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	[2]	113.5	106.9
CSCA | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	[2]	92.4	120.4
CSCA | Nutrition
Disaggregation of Revenue [Line Items]
Net sales	[2]	92	102.2
CSCA | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	[2]	75.5	85.8
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	[2]	73.7	55.3
CSCA | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	[2]	53.3	46.7
CSCA | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	7.8	6.4
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	18.3	22.3
CSCI
Disaggregation of Revenue [Line Items]
Net sales		369.5	382.7
CSCI | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales		42.9	84.1
CSCI | Digestive health
Disaggregation of Revenue [Line Items]
Net sales		8.5	6
CSCI | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales		49	46.8
CSCI | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales		50.3	43.6
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales		25.5	23.2
CSCI | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales		107	94.7
CSCI | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales		59	48.5
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	$ 27.3	$ 35.8
[1]	Derived from the location of the entity that sells to a third party.
[2]	Includes net sales from our OTC contract manufacturing business.
[3]	Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
[4]	Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,010	$ 1,083.3
Contract manufacturing
Disaggregation of Revenue [Line Items]
Net sales		$ 63.1	$ 49.2
[1]	Derived from the location of the entity that sells to a third party.

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of Contract Balances (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Short-term contract assets	$ 18.4	$ 19.7

Acquisitions (Details)

Acquisitions (Details) € in Millions, $ in Millions	Oct. 30, 2020EUR (€)brand	Oct. 30, 2020USD ($)brand	Feb. 13, 2020USD ($)	Jan. 03, 2020USD ($)
Sanofi Brands
Business Acquisition [Line Items]
Number of brands acquired | brand	3	3
Purchase price paid	€ 53.3	$ 62.3
Useful life of intangible assets	18 years 9 months 18 days	18 years 9 months 18 days
Steripod
Business Acquisition [Line Items]
Purchase price paid				$ 26
Brand | Sanofi Brands
Business Acquisition [Line Items]
Intangible assets acquired		$ 52.5
Brand | Dexsil
Business Acquisition [Line Items]
Intangible assets acquired			$ 8
Useful life of intangible assets			25 years
Brand | Steripod
Business Acquisition [Line Items]
Intangible assets acquired				$ 25.1
Useful life of intangible assets				25 years

Acquisitions and Divestitures -

Acquisitions and Divestitures - Oral Care Assets of High Ridge Brands and Ranir Global Holdings,LLC Acquisitions (Details) - USD ($) $ in Millions	Dec. 31, 2020	Apr. 01, 2020	Dec. 31, 2020	Apr. 03, 2021
Estimated fair value of assets acquired and liabilities assumed:
Goodwill	$ 3,095.7		$ 3,095.7	$ 3,052.3
Oral Care Assets of High Ridge Brands (Dr. Fresh)
Business Acquisition [Line Items]
Cash consideration	106.2	$ 113	106.2
Prepayment of contract consideration for transitional services	2		2
Estimated fair value of assets acquired and liabilities assumed:
Accounts receivable	13.1		13.1
Inventories	22.2		22.2
Prepaid expenses and other current assets	0.4		0.4
Property, plant and equipment, net	0.7		0.7
Operating lease assets	2.6		2.6
Goodwill	17.2		17.2
Definite-lived intangible assets	66.1		66.1
Total assets	122.3		122.3
Accounts payable	6.1		6.1
Other accrued liabilities	3.8		3.8
Payroll and related taxes	0.7		0.7
Accrued customer programs	3		3
Other non-current liabilities	2.5		2.5
Total liabilities	16.1		16.1
Net assets acquired	106.2		106.2
Useful life of intangible assets		17 years 9 months 18 days
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Distribution and License Agreements and Supply Agreements
Estimated fair value of assets acquired and liabilities assumed:
Definite-lived intangible assets	2.2		2.2
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Developed product technology, formulations, and product rights
Estimated fair value of assets acquired and liabilities assumed:
Definite-lived intangible assets	0.1		0.1
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Customer relationships and distribution networks
Estimated fair value of assets acquired and liabilities assumed:
Definite-lived intangible assets	20.6		20.6
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Trademarks, trade names, and brands
Estimated fair value of assets acquired and liabilities assumed:
Definite-lived intangible assets	$ 43.2		$ 43.2

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information (Details) $ in Millions	3 Months Ended
	Mar. 28, 2020USD ($)
Business Combinations [Abstract]
Net sales	$ 1,119.1
Income from continuing operations	$ 62.6

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill, Beginning Balance		$ 3,095.7
Purchase accounting adjustments		0
Currency translation adjustments		(43.4)
Goodwill, Ending Balance		3,052.3
CSCA
Goodwill [Roll Forward]
Goodwill, Beginning Balance		1,905
Purchase accounting adjustments		2.4
Currency translation adjustments		(1.9)
Goodwill, Ending Balance		1,905.5
CSCI
Goodwill [Roll Forward]
Goodwill, Beginning Balance	[1]	1,190.7
Purchase accounting adjustments	[1]	(2.4)
Currency translation adjustments	[1]	(41.5)
Goodwill, Ending Balance	[1]	1,146.8
Accumulated impairments		$ (868.4)	$ (868.4)
[1]	We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and April 3, 2021.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible categories (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	$ 7		$ 7
Gross	3,785.7		3,883
Accumulated Amortization	1,419.4		1,401.5
Total other intangible assets	3,792.7		3,890
Intangible assets amortization expense	53.2	$ 52.6
Distribution and license agreements and supply agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	73.2		74.8
Accumulated Amortization	55.1		55.4
Developed product technology, formulations, and product rights
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	301.8		303.3
Accumulated Amortization	180.5		177.3
Customer relationships and distribution networks
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,873.9		1,920.5
Accumulated Amortization	830.9		823.7
Trademarks, trade names, and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,534.4		1,581.5
Accumulated Amortization	350.5		342.2
Non-compete agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	2.4		2.9
Accumulated Amortization	2.4		2.9
Trademarks, trade names, and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	4.3		4.3
In-process research and development
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	$ 2.7		$ 2.7

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 648.2	$ 574.1
Work in process	234.7	220.4
Raw materials	253.2	264.9
Total inventories	$ 1,136.1	$ 1,059.4

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments at Fair Value (Details) - Measured at fair value on a recurring basis - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Level 1
Assets:
Investment securities	$ 2.9	$ 2.5
Foreign currency forward contracts	0	0
Cross-currency swap	0	0
Total assets	2.9	2.5
Liabilities:
Foreign currency forward contracts	0	0
Total liabilities	0	0
Level 2
Assets:
Investment securities	0	0
Foreign currency forward contracts	7.2	9.8
Cross-currency swap	5.7	6.3
Total assets	12.9	16.1
Liabilities:
Foreign currency forward contracts	6.5	7.9
Total liabilities	6.5	7.9
Level 3
Assets:
Investment securities	0	0
Foreign currency forward contracts	0	0
Cross-currency swap	0	0
Total assets	0	0
Liabilities:
Foreign currency forward contracts	0	0
Total liabilities	$ 0	$ 0

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Royalty Pharma Contingent Milestone Payments - Measured on a recurring basis - Level 3 $ in Millions	3 Months Ended
	Mar. 28, 2020USD ($)
Royalty Pharma Contingent Milestone Payments
Beginning balance	$ 95.3
Change in fair value	1.6
Ending balance	$ 96.9

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers among level 1, 2, and 3	$ 0		$ 0
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment		$ 1.6
Estimated fair valued contingent milestone payment		$ 96.9	$ 0	$ 95.3
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility		35.00%
Rate of return		7.29%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	$ 2,918.8	$ 2,924.9
Public Bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,863.7	3,031.1
Private placement note | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Private placement note	176.6	177.5
Reported Value Measurement | Public Bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,760	2,760
Reported Value Measurement | Private placement note | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Private placement note	$ 158.8	$ 164.9

Investments (Details)

Investments (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020
Other (income) expense, net
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method, other expense (income)		$ 0	$ 2.9
Equity securities, equity method, other expense (income)		0.7	$ (0.7)
Prepaid expenses and other current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method		2.9		$ 2.5
Other non-current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method	[1]	1.5		1.9
Equity securities, equity method, other non-current assets		$ 69.1		$ 69.8
[1]	(1)     Measured at fair value using the Net Asset Value practical expedient.

Discontinued Operations (Detail

Discontinued Operations (Details) - RX - Discontinued Operations, Disposed of by Sale - USD ($)	Mar. 01, 2021	Apr. 03, 2021
Discontinued Operations
Total consideration	$ 1,550,000,000
Cash consideration	1,500,000,000
Potential R&D milestone payments and contingent purchase obligations assumed by purchaser	$ 50,000,000
Transition service period	24 months
Supply agreement term	4 years
Supply agreement, extension period	7 years
Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent)	50.00%
Aggregate cap on buyer's obligation for certain pre-closing liabilities	$ 50,000,000
Separation costs		$ 9,300,000

Discontinued Operations - Resul

Discontinued Operations - Results of Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - RX - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$ 200.1	$ 257.7
Cost of sales	138.3	165.8
Gross profit	61.8	91.9
Distribution	3.3	4
Research and development	13.4	13.6
Selling	7.4	7.3
Administration	18.2	6.5
Other operating expense (income)	(0.9)	1.1
Total operating expenses	41.4	32.5
Operating income	20.4	59.4
Interest expense, net	0.6	1.4
Other (income) expense, net	(1.5)	0.7
Income before income taxes	21.3	57.3
Income tax expense (benefit)	(14)	8.5
Income from discontinued operations, net of tax	$ 35.3	$ 48.8

Discontinued Operations - Cash

Discontinued Operations - Cash Flow Information (Details) - Discontinued Operations, Disposed of by Sale - RX - USD ($) $ in Millions	Mar. 08, 2021	Dec. 31, 2020	Apr. 03, 2021	Mar. 28, 2020
Cash flows from discontinued operations operating activities:
Depreciation and amortization			$ 15.3	$ 24
Cash flows from discontinued operations investing activities:
Asset acquisitions	$ (53.3)	$ (16.4)	(69.7)	(0.1)
Additions to property, plant and equipment			$ (3.2)	$ (2.9)

Discontinued Operations - Addit

Discontinued Operations - Additional Cash Flow Information (Details) $ in Millions	Mar. 08, 2021USD ($)	Dec. 31, 2020USD ($)	May 15, 2015brand	Apr. 03, 2021USD ($)	Mar. 28, 2020USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ANDAs acquired | brand			2
Discontinued Operations, Disposed of by Sale | RX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset acquisitions | $	$ 53.3	$ 16.4		$ 69.7	$ 0.1

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020	Mar. 28, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ 9.6	$ 10	$ 18.7	$ 9.8
Current assets held for sale	1,989.1	666.9
Non-current assets held for sale	0	1,364
Current liabilities held for sale	450	419.6
Non-current liabilities held for sale	0	108.3
Discontinued Operations, Disposed of by Sale | RX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	9.6	10
Accounts receivable, net of allowance for credit losses of $1.1 and $1.1, respectively	419.9	460.7
Inventories	136.8	140.8
Prepaid expenses and other current assets	29.7	55.4
Current assets held for sale		666.9
Property, plant and equipment, net	126.4	131.4
Operating lease assets	29.6	31.3
Goodwill and indefinite-lived intangible assets	678.7	681.2
Definite-lived intangible assets, net	533	492.8
Deferred income taxes	3	3.6
Other non-current assets	22.4	23.7
Non-current assets held for sale		1,364
Total assets held for sale	1,989.1	2,030.9
Accounts payable	101.1	92.2
Payroll and related taxes	16.7	22.3
Accrued customer programs	185.9	237.4
Other non-current assets	47.4	67.2
Current indebtedness	0.5	0.5
Current liabilities held for sale		419.6
Other non-current assets	0.6	0.7
Deferred income taxes	2.9	3.1
Other non-current liabilities	94.9	104.5
Non-current liabilities held for sale		108.3
Total liabilities held for sale	450	527.9
Allowance for credit losses	$ 1.1	$ 1.1

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) € in Millions, $ in Millions	3 Months Ended
	Apr. 03, 2021EUR (€)	Apr. 03, 2021USD ($)	Dec. 31, 2020USD ($)
Cross-currency swap
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	€ 450	$ 498
Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		672.7	$ 867.7
Maximum remaining maturity of foreign currency derivatives	60 months
European Euro (EUR) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		270.7	312.6
Israeli Shekel (ILS) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		74.1	94.4
United States Dollar (USD) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		63.4	101.5
Chinese Yuan (CNY) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		50.4	49.1
British Pound (GBP) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		44.8	92.3
Danish Krone (DKK) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		44	65.2
Swedish Krona (SEK) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		30.1	41.2
Canadian Dollar (CAD) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		27.8	36.8
Polish Zloty (PLZ) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		18.3	21.8
Mexican Peso (MPX) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		14.8	15.6
Norwegian Krone (NOK) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		9.7	7.8
Australian Dollar (AUD) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		9.1	11.3
Romanian New Leu (RON) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		4.8	3.6
Switzerland Franc (CHF) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		4.6	8.2
Turkish Lira (TRY) | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		3.7	4
Other | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives		$ 2.4	$ 2.3

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Designated derivatives:
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 11.7	$ 11.8
Designated derivatives: | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	5.6	5
Designated derivatives: | Other non-current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	0.4	0.5
Designated derivatives: | Other non-current assets | Cross-currency swap
Derivatives, Fair Value [Line Items]
Asset Derivatives	5.7	6.3
Designated derivatives: | Other accrued liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability Derivatives	3.6	5.5
Non-designated derivatives: | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	1.2	4.3
Non-designated derivatives: | Other accrued liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 2.9	$ 2.4

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021		Mar. 28, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	$ 1.7	[1]	$ 9.3
Amount of Gain/(Loss) Reclassified from AOCI into Earnings	(2.8)		(1.9)
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net	0		0.4
Net gain expected to be reclassified out of AOCI into earnings in the next 12 months	(13.4)
Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	0		0
Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness	0		0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0		0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	1		2.8
Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	(0.9)		(0.4)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0		0
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	(1.4)		(1)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.1		0.4
Other income (expense), net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	(0.1)
Interest Rate Swap | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	0	[1]	0
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	(0.5)		(0.5)
Interest Rate Swap | Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	0		0
Interest Rate Swap | Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	0		0
Foreign currency forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	1.7	[1]	9.3
Cross-currency swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Net investment hedges	$ (0.5)	[1]	$ (15)
[1]	Net loss of $13.4 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) - Non-designated derivatives: - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	$ (3.6)	$ 7.1
Foreign currency forward contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	(4.8)	6.2
Foreign currency forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	$ 1.2	$ 0.9

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	[1]	$ 1,010	$ 1,083.3
Cost of sales		641.6	689.6
Interest expense, net		32	28.9
Other (income) expense, net		2.4	1.7
Net Sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		(0.9)	(0.4)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0	0
Cost of sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		(1.4)	(1)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0.1	0.4
Interest expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		0	0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0	0
Other (income) expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		0	0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		(0.1)	0
Interest Rate Swap | Net Sales
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		0	0
Interest Rate Swap | Cost of sales
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		0	0
Interest Rate Swap | Interest expense, net
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		(0.5)	(0.5)
Interest Rate Swap | Other (income) expense, net
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		$ 0	$ 0
[1]	Derived from the location of the entity that sells to a third party.

Leases - Balance Sheet Location

Leases - Balance Sheet Location of Assets and Liabilities (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating lease assets	$ 149.7	$ 154.7
Finance leases	32.2	29.8
Right-of-Use Asset	181.9	184.5
Operating lease liability, current	27.1	28.3
Finance lease liability, current	5.2	6.7
Operating lease liability, noncurrent	128.2	132.5
Finance lease liability, noncurrent	24.3	20.2
Present value of lease liabilities	184.8	187.7
Total operating lease liabilities	155.3	160.8
Total finance lease liabilities	$ 29.5	$ 26.9
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssets	us-gaap:OtherAssets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent	us-gaap:OtherLiabilitiesCurrent
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:DebtCurrent	us-gaap:DebtCurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities	Other non-current liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, less current portion	Long-term debt, less current portion
Unallocated
Lessee, Lease, Description [Line Items]
Operating lease assets	$ 42.6	$ 44.4
Finance leases	7.2	7.2
Total operating lease liabilities	47.7	49.8
Total finance lease liabilities	7.3	7.4
CSCA | Operating Segments
Lessee, Lease, Description [Line Items]
Operating lease assets	74.2	75.9
Finance leases	16.3	16.7
Total operating lease liabilities	73.9	75.8
Total finance lease liabilities	16.7	17
CSCI | Operating Segments
Lessee, Lease, Description [Line Items]
Operating lease assets	32.9	34.4
Finance leases	8.7	5.9
Total operating lease liabilities	33.7	35.2
Total finance lease liabilities	$ 5.5	$ 2.5

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Leases [Abstract]
Operating leases	[1]	$ 9.8	$ 9.6
Finance leases
Amortization		1.5	1
Interest		0.2	0.2
Total finance leases		$ 1.7	$ 1.2
[1]	(1) Includes short-term leases and variable lease costs, which are immaterial.

Leases - Annual Future Maturiti

Leases - Annual Future Maturities of Leases (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	$ 24
2022	26.2
2023	18.9
2024	15.9
2025	13.9
After 2025	80.5
Total lease payments	179.4
Less: Interest	24.1
Present value of lease liabilities	155.3	$ 160.8
Finance Lease, Liability, Payment, Due [Abstract]
2021	4.5
2022	5.5
2023	3.8
2024	2.3
2025	2.2
After 2025	15.8
Total lease payments	34.1
Less: Interest	4.6
Present value of lease liabilities	29.5	26.9
Lease Liabilities, Payments, Due [Abstract]
2021	28.5
2022	31.7
2023	22.7
2024	18.2
2025	16.1
After 2025	96.3
Total lease payments	213.5
Less: Interest	28.7
Present value of lease liabilities	$ 184.8	$ 187.7

Leases - Weighted Average Lease

Leases - Weighted Average Lease Terms and Discount Rates (Details)	Apr. 03, 2021	Mar. 28, 2020
Leases [Abstract]
Weighted-average remaining lease term - Operating leases	10 years 6 months 7 days	5 years 11 months 23 days
Weighted-average lease term - Finance leases	9 years 3 months 21 days	10 years 1 month 6 days
Weighted-average discount rate - Operating lease (percent)	2.97%	3.97%
Weighted-average discount rate - Finance lease (percent)	2.76%	3.42%

Leases - Lease Cash Flow Classi

Leases - Lease Cash Flow Classifications (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Leases [Abstract]
Operating cash flows for operating leases	$ 10	$ 8.9
Operating cash flows for finance leases	0.2	0.2
Financing cash flows for finance leases	1.3	0.9
Leased assets obtained in exchange for new finance lease liabilities	4.2	1.5
Leased assets obtained in exchange for new operating lease liabilities	$ 3.9	$ 4.9

Indebtedness - Schedule of Borr

Indebtedness - Schedule of Borrowings Outstanding (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Notes and Bonds		$ 2,918.8	$ 2,924.9
Other financing		60.1	57.4
Unamortized premium (discount), net		(1.5)	(0.3)
Deferred financing fees		(16.3)	(17.1)
Total borrowings outstanding		3,561.1	3,564.9
Current indebtedness		(35.8)	(37.3)
Long-term debt, less current portion		3,525.3	3,527.6
2019 Term loan due August 15, 2022
Debt Instrument [Line Items]
Term loans		$ 600	600
5.105% Senior note due July 28, 2023
Debt Instrument [Line Items]
Series	[1]	July 28, 2023(1)
Interest rate, stated percentage		5.105%
Notes and Bonds	[1]	$ 158.8	164.9
4.00% unsecured senior notes due November 15, 2023
Debt Instrument [Line Items]
Series		November 15, 2023
Interest rate, stated percentage		4.00%
Notes and Bonds		$ 215.6	215.6
3.9% senior note due December 15, 2024
Debt Instrument [Line Items]
Series		December 15, 2024
Interest rate, stated percentage		3.90%
Notes and Bonds		$ 700	700
4.375% senior note due March 15, 2026
Debt Instrument [Line Items]
Series		March 15, 2026
Interest rate, stated percentage		4.375%
Notes and Bonds		$ 700	700
3.150% Senior Notes due June 15, 2030
Debt Instrument [Line Items]
Series		June 15, 2030
Interest rate, stated percentage		3.15%
Notes and Bonds		$ 750	750
5.30% unsecured senior notes due November 15, 2043
Debt Instrument [Line Items]
Series		November 15, 2043
Interest rate, stated percentage		5.30%
Notes and Bonds		$ 90.5	90.5
4.9% senior notes due December 15, 2044
Debt Instrument [Line Items]
Series		December 15, 2044
Interest rate, stated percentage		4.90%
Notes and Bonds		$ 303.9	$ 303.9
[1]	Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Indebtedness - Additional Infor

Indebtedness - Additional Information (Details)	Dec. 08, 2020USD ($)	Apr. 03, 2021USD ($)	Dec. 31, 2020USD ($)	Jun. 17, 2020USD ($)promissoryNote	Mar. 08, 2018USD ($)
Debt Instrument [Line Items]
Outstanding balance		$ 0	$ 0
2018 Revolver due March 8, 2023
Debt Instrument [Line Items]
Face amount of debt					$ 1,000,000,000
Borrowings on line of credit		$ 0	$ 0
Kazmira, LLC
Debt Instrument [Line Items]
Promissory notes				$ 34,300,000
Number of promissory notes | promissoryNote				2
Kazmira, LLC | Note due November 2020
Debt Instrument [Line Items]
Promissory notes				$ 3,700,000
Debt repaid	$ 3,700,000
Kazmira, LLC | Note due May 2021
Debt Instrument [Line Items]
Promissory notes				5,800,000
Kazmira, LLC | Note due November 2021
Debt Instrument [Line Items]
Promissory notes				$ 24,800,000

Earnings Per Share and Shareh_3

Earnings Per Share and Shareholders' Equity (Details) - USD ($)	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Oct. 31, 2018
Numerator:
Income from continuing operations	$ 2,800,000	$ 57,600,000
Income from discontinued operations, net of tax	35,300,000	48,800,000
Net income	$ 38,100,000	$ 106,400,000
Denominator:
Weighted average shares outstanding for basic EPS	133,200,000	136,200,000
Dilutive effect of share-based awards (in shares)	1,400,000	1,100,000
Weighted average shares outstanding for diluted EPS	134,600,000	137,300,000
Anti-dilutive share-based awards excluded from computation of diluted EPS (shares)	1,800,000	1,700,000
Stock repurchase program, authorized amount			$ 1,000,000,000
Repurchases of ordinary shares (shares)	0	0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	$ 5,655,100	$ 5,803,800
OCI before reclassifications	(121,100)
Amounts reclassified from AOCI	2,800
Other comprehensive income (loss), net of tax	(118,300)	(103,500)
Balance, ending	5,558,000	5,786,400
Fair Value of Derivative Financial Instruments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	(700)
OCI before reclassifications	(8,800)
Amounts reclassified from AOCI	2,800
Other comprehensive income (loss), net of tax	(6,000)
Balance, ending	(6,700)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	407,300
OCI before reclassifications	(111,600)
Amounts reclassified from AOCI	0
Other comprehensive income (loss), net of tax	(111,600)
Balance, ending	295,700
Post-Retirement and Pension Liability Adjustments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	(11,600)
OCI before reclassifications	(700)
Amounts reclassified from AOCI	0
Other comprehensive income (loss), net of tax	(700)
Balance, ending	(12,300)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	395,000	139,400
Other comprehensive income (loss), net of tax	(118,300)	(103,500)
Balance, ending	$ 276,700	$ 35,900

Income Taxes (Details)

Income Taxes (Details) € in Millions, $ in Millions

May 03, 2021

Feb. 26, 2021USD ($)

Jan. 13, 2021USD ($)

Dec. 19, 2020USD ($)

May 07, 2020USD ($)

Aug. 15, 2017USD ($)

Apr. 03, 2021USD ($)

Mar. 28, 2020

Dec. 31, 2020USD ($)

Dec. 31, 2013

Dec. 31, 2012USD ($)

Dec. 31, 2011USD ($)

Dec. 31, 2010USD ($)

Dec. 31, 2009USD ($)

Dec. 29, 2020USD ($)

Apr. 26, 2019USD ($)

Nov. 29, 2018EUR (€)

Income Tax Contingency [Line Items]

Effective income tax rate reconciliation, percent

84.00%

(0.40%)

Income tax examination, penalties and interest expense

$ 134.1

$ 24.7

$ 40.1

$ 41.8

$ 27.5

Cumulative deferred charge related to tax litigation

$ 111.6

Royalty conceded on all omeprazole sales as a percent of refund claims (percent)

5.24%

IRS Notice of Proposed Audit Adjustment from 2013, 2014 and 2015

$ 141.6

IRS Notice of Proposed Audit Adjustment for ANDA from 2013, 2014 and 2015

21.9

Income tax examination, estimate of additional tax expense, excluding interest and penalties

$ 18

$ 7

Income tax examination, debts subject to limit of deductibility of interest expense

7,500

Interest rate cap on debts for U.S. Federal tax purposes, as percent of Applicable Federal Rate

130.00%

Income tax examination, reduction in blended interest rate due to cap for U.S. Federal tax purposes

4.00%

IRS notice of proposed audit adjustment to reduce deductible interest expense for fiscal years 2014 and 2015

$ 414.7

IRS notice of proposed audit adjustment, increase to gross sales revenue for the 2013, 2014 and 2015 tax years

$ 99.5

IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty

$ 843

IRS notice of proposed adjustment, penalty (percent)

40.00%

Subsequent Event

Income Tax Contingency [Line Items]

Interest rate cap on debts for U.S. Federal tax purposes, as percent of Applicable Federal Rate, no longer pursued

130.00%

Minimum

Income Tax Contingency [Line Items]

Income tax examination, estimate of additional tax expense, excluding interest and penalties

24

Maximum

Income Tax Contingency [Line Items]

Income tax examination, estimate of additional tax expense, excluding interest and penalties

$ 112

Revenue Commissioners, Ireland

Income Tax Contingency [Line Items]

Irish Revenue notice of amended assessment unsettled assessed audit liability | €

€ 1,643

Irish Revenue proposed tax rate on net chargeable gain realized (percent)

33.00%

Irish Revenue tax rate applied to trading income (percent)

12.50%

Unsettled audit assessment from income tax examination | €

€ 1,636

Israel Tax Authority

Income Tax Contingency [Line Items]

Unsettled audit assessment from income tax examination

$ 63.8

Contingencies (Details)

Contingencies (Details) $ in Millions, ₪ in Billions

Apr. 13, 2021lawsuittender

Apr. 11, 2021complaint

May 31, 2019individual

Jan. 16, 2019defendantgenericPrescriptionPharmaceutical

Jun. 28, 2017ILS (₪)caseindividualgenericPrescriptionPharmaceutical$ / ₪

Jun. 28, 2017USD ($)caseindividualgenericPrescriptionPharmaceutical$ / ₪

Sep. 30, 2020lawsuit

Apr. 03, 2021USD ($)claimcasedefendantgenericPrescriptionPharmaceuticalretailercomplaintclassappealindividuallawsuit

Dec. 31, 2019case

Dec. 31, 2018casebrand

Dec. 31, 2017case

Dec. 15, 2020manufacturerbrandpharmaceuticalCompany

Dec. 14, 2020manufacturer

Dec. 11, 2020manufacturer

Sep. 04, 2020manufacturer

Aug. 27, 2020manufacturer

Jul. 14, 2020casebrandmanufacturer

Jul. 09, 2020pharmaceuticalCompany

Jun. 30, 2020manufacturer

Jun. 10, 2020employeeplaintiffGroupmanufacturer

Jun. 09, 2020manufacturer

May 31, 2020individualmanufacturerhealthPlan

Mar. 01, 2020defendant

Dec. 27, 2019defendant

Dec. 23, 2019defendant

Dec. 16, 2019defendant

Dec. 11, 2019defendant

Nov. 14, 2019class

Jul. 18, 2019individualmanufacturerhealthPlan

Apr. 30, 2019manufacturergenericPrescriptionPharmaceuticalpharmaceuticalProduct

Dec. 21, 2018manufacturergenericPrescriptionPharmaceutical

Aug. 03, 2018genericPrescriptionPharmaceuticalmanufacturer

Jul. 31, 2018individual

Jan. 22, 2018supermarketmanufacturergenericPrescriptionPharmaceutical

Jun. 30, 2017case

Jun. 21, 2017individualgenericPrescriptionPharmaceuticalclass

Loss Contingencies [Line Items]

Number of putative classes | class

3

3

3

Number of sets of class action complaints | complaint

2

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

6

Number of individuals | individual

11

Number of current or former directors and officers | individual

11

Loss accrual for litigation contingencies | $

$ 65

Insurance recovery receivable | $

$ 65

States' May 2019 Case Alleging Conspiracy (which does not Name Perrigo a Defendant)

Loss Contingencies [Line Items]

Number of products included in expedited cases | brand

120

Number of manufacturers

35

Overarching Conspiracy Class Actions

Loss Contingencies [Line Items]

Number of manufacturers

27

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

135

Number of formulations of products manufactured by the Company | genericPrescriptionPharmaceutical

2

Number of products manufactured by the Company | pharmaceuticalProduct

1

Number of cases included in expedited schedule | case

0

Price-Fixing Lawsuit, Drugstore Chain

Loss Contingencies [Line Items]

Number of manufacturers

45

45

Number of products manufactured by the Company | brand

63

Number of other pharmaceutical companies | pharmaceuticalCompany

39

Price-Fixing Lawsuit, Suffolk County of New York

Loss Contingencies [Line Items]

Number of manufacturers

35

Price-Fixing Lawsuit, Drug Wholesaler and Distributor

Loss Contingencies [Line Items]

Number of manufacturers

39

State Attorney General Complaint

Loss Contingencies [Line Items]

Number of manufacturers

35

Number of former employees | employee

1

Number of current employees | employee

1

Number of additional states and territories | plaintiffGroup

50

Canadian Class Action Complaint

Loss Contingencies [Line Items]

Number of manufacturers

29

Price-Fixing Lawsuit, Supermarket Chains

Loss Contingencies [Line Items]

Number of manufacturers

45

35

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

31

Number of supermarket chains | supermarket

3

Price-Fixing Lawsuit, Supermarket Chains, Amended Complaint

Loss Contingencies [Line Items]

Number of manufacturers

39

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

33

Price-fixing Lawsuit, Managed Care Organization

Loss Contingencies [Line Items]

Number of manufacturers

27

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

17

Price-fixing Lawsuit, Health Insurance Carrier

Loss Contingencies [Line Items]

Number of manufacturers

25

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

30

Number of defendants | defendant

30

Price-fixing Lawsuit, Healthcare Service Company

Loss Contingencies [Line Items]

Number of co-defendants | defendant

38

Price-fixing Lawsuit, Medicare Advantage Claims Recovery Company

Loss Contingencies [Line Items]

Number of co-defendants | defendant

39

Price-fixing Lawsuit, Several Counties in New York

Loss Contingencies [Line Items]

Number of other pharmaceutical companies | pharmaceuticalCompany

45

Number of co-defendants | defendant

28

Price-fixing Lawsuit, Healthcare Management Organization

Loss Contingencies [Line Items]

Number of co-defendants | defendant

25

Price-fixing Lawsuit, Harris County of Texas

Loss Contingencies [Line Items]

Number of co-defendants | defendant

29

Highfields Capital I LP, et al. v. Perrigo Company plc, et al.

Loss Contingencies [Line Items]

Number of cases alleging only state law claims | lawsuit

1

Price-fixing Lawsuit, Health Plans

Loss Contingencies [Line Items]

Number of manufacturers

53

Number of health plans | healthPlan

7

87

Number of dozens of manufacturers

3

Number of individuals | individual

17

17

Blackrock Global Complaint

Loss Contingencies [Line Items]

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

6

Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al.

Loss Contingencies [Line Items]

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

6

6

Number of cases voluntarily dismissed | case

2

2

Number of current or former directors and officers | individual

11

11

Damages sought by plaintiff

₪ 2.7

$ 760

Foreign currency exchange rate, remeasurement | $ / ₪

0.28

0.28

Ranitidine Litigation

Loss Contingencies [Line Items]

Number of master complaints | complaint

3

Number of master complaints naming the company | complaint

3

Number of appeals of master complaints | appeal

1

Number of appeals of personal injury claims | appeal

2

Carmignac, First Manhattan and Similar Cases

Loss Contingencies [Line Items]

Number of cases with similar factual allegations | case

7

First Manhattan and Similar Cases

Loss Contingencies [Line Items]

Number of generic prescription pharmaceuticals | case

6

Mason Capital, Pentwater and Similar Cases

Loss Contingencies [Line Items]

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

6

Number of cases with similar factual allegations | case

8

Number of current or former directors and officers | case

11

Harel Insurance and TIAA-CREF Cases

Loss Contingencies [Line Items]

Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical

6

Number of cases with similar factual allegations | case

2

Number of individuals | individual

11

Number of current or former directors and officers | individual

13

Number of defendants added | defendant

2

Other Cases Related to Events in 2015-2017

Loss Contingencies [Line Items]

Number of cases with similar factual allegations | case

1

Number of overlapped cases | case

3

In Israel (Cases Related to Events in 2015-2017)

Loss Contingencies [Line Items]

Number of cases | case

3

Number of cases voluntarily dismissed | case

1

1

Number of cases stayed | brand

1

In Israel (Cases Related to Irish Tax Events)

Loss Contingencies [Line Items]

Number of cases stayed | case

2

In the United States (Cases Related to Irish Tax Events)

Loss Contingencies [Line Items]

Number of defendants | individual

3

Number of defendants added | individual

1

Acetaminophen Litigation

Loss Contingencies [Line Items]

Number of lawsuits | lawsuit

1

Number of claims for indemnification or defense | claim

16

Number of retailers | retailer

10

Subsequent Event | Talcum Powder Litigation

Loss Contingencies [Line Items]

Number of lawsuits | lawsuit

51

Number of tenders accepted for a portion of the defense costs and liability from a retailer | tender

1

Subsequent Event | Ranitidine Litigation

Loss Contingencies [Line Items]

Number of personal injury lawsuits | complaint

187

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Restructuring Charges [Abstract]
Restructuring charges	$ 1,700	$ 0
Restructuring Reserve [Roll Forward]
Beginning balance	9,100	19,500
Additional charges	1,800	0
Payments	(4,400)	(3,500)
Non-cash adjustments	(300)	0
Ending balance	$ 6,200	$ 16,000

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Assets		$ 11,324.8		$ 11,488.4
Net sales	[1]	1,010	$ 1,083.3
Operating Income (Loss)		51.4	86.4
Intangible Asset Amortization		53.2	52.6
Unallocated
Segment Reporting Information [Line Items]
Net sales		0	0
Operating Income (Loss)		(61.6)	(60.7)
Intangible Asset Amortization		0	0
Held-for-sale
Segment Reporting Information [Line Items]
Assets		1,989.1		2,030.9
CSCA
Segment Reporting Information [Line Items]
Assets		4,738.9		4,585.1
Net sales	[2]	640.5	700.6
CSCA | Operating Segments
Segment Reporting Information [Line Items]
Net sales		640.5	700.6
Operating Income (Loss)		95.6	122.1
Intangible Asset Amortization		12.9	14.3
CSCI
Segment Reporting Information [Line Items]
Assets		4,596.8		$ 4,872.4
Net sales		369.5	382.7
CSCI | Operating Segments
Segment Reporting Information [Line Items]
Net sales		369.5	382.7
Operating Income (Loss)		17.4	25
Intangible Asset Amortization		$ 40.3	$ 38.3
[1]	Derived from the location of the entity that sells to a third party.
[2]	Includes net sales from our OTC contract manufacturing business.